Johan Falkenburg
Emeritus hoogleraar Experimentele Hematologie, in het bijzonder de immunotherapie van hematologische ziekten
- Naam
- Prof.dr. J.H.F. Falkenburg
- j.h.f.falkenburg@lumc.nl
- ORCID iD
- 0000-0002-9819-4813
De behandeling van kwaadaardige hematologische ziekten was tot nu toe gestoeld op therapie met chemotherapie en/of bestraling. Zowel uit basaal wetenschappelijk onderzoek, als uit klinische observaties is gebleken dat kwaadaardige cellen zeer efficiënt gedood kunnen worden door afweercellen, en met name T-lymfocyten. Door stapsgewijs alle facetten van laboratoriumonderzoek te doorlopen tot aan de klinische toepassing van afweercellen tegen kankercellen, zal het mogelijk zijn een nieuwe dimensie toe te voegen aan de behandeling van kwaadaardige bloedziekten. De vertaalslag van onderzoek naar therapie met behulp van cellulaire producten is een nieuwe fase in de ontwikkeling van therapeutica.
Op 22 februari 2000 sprak hij zijn oratie uit, getiteld: 'Immunotherapie en de vertaalslag in de medische wetenschap'.
Emeritus hoogleraar Experimentele Hematologie, in het bijzonder de immunotherapie van hematologische ziekten
- Faculteit Geneeskunde
- Divisie 2
- Hematologie
- Hematologie algemeen
Contact
- (2024), Immunological differences between monophasic and biphasic synovial sarcoma with implications for immunotherapy.
- Koster, E.A.S.; Borne, P.A. von dem; Balen, P. van; Marijt, E.W.A.; Tjon, J.M.L.; Snijders, T.J.F.; Lammeren, D. van; Veelken, H.; Falkenburg, J.H.F.; Halkes, C.J.M. & Wreede, L.C. de (2024), Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation, Frontiers in Immunology 15.
- Koster, E.A.S.; Borne, P.A. von dem; Balen, P. van; Egmond, E.H.M. van; Marijt, E.W.A.; Veld, S.A.J.; Jedema, I.; Snijders, T.J.F.; Lammeren, D. van; Veelken, H.; Falkenburg, J.H.F.; Wreede, L.C. de & Halkes, C.J.M. (2023), Competitive repopulation and allo-immunologic pressure determine chimerism kinetics after T Cell-depleted allogeneic stem cell transplantation and donor lymphocyte infusion, Transplantation and Cellular Therapy 29(4).
- Meeuwsen, M.H.; Wouters, A.K.; Wachsmann, T.L.A.; Hagedoorn, R.S.; Kester, M.G.D.; Remst, D.F.G.; Steen, D.M. van der; Ru, A.H. de; Hees, E.P. van; Kremer, M.; Griffioen, M.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain, Journal of Hematology and Oncology 16(1).
- Rooij, M.A.J. de; Remst, D.F.G.; Steen, D.M. van der; Wouters, A.K.; Hagedoorn, R.S.; Kester, M.G.D.; Meeuwsen, M.H.; Wachsmann, T.L.A.; Ru, A.H. de; Veelen, P.A. van; Verdegaal, E.M.E.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), A library of cancer testis specific T cell receptors for T cell receptor gene therapy, Molecular Therapy - Oncolytics 28.
- Amerongen, R.A. van; Morton, L.T.; Chaudhari, U.G.; Remst, D.F.G.; Hagedoorn, R.S.; Berg, C.W. van den; Freund, C.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential, Molecular Therapy - Methods and Clinical Development 28: 249-261.
- Amerongen, R.A. van; Tuit, S.; Wouters, A.K.; Meent, M. van de; Siekman, S.L.; Meeuwsen, M.H.; Wachsmann, T.L.A.; Remst, D.F.G.; Hagedoorn, R.S.; Steen, D.M. van der; Ru, A.H. de; Verdegaal, E.M.E.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer, Frontiers in Immunology 14.
- Huisman, W.; Roex, M.C.J.; Hageman, L.; Koster, E.A.S.; Veld, S.A.J.; Hoogstraten, C.; Balen, P. van; Egmond, H.M. van; Bergen, C.A.M. van; Einsele, H.; Germeroth, L.; Amsen, D.; Falkenburg, J.H.F. & Jedema, I. (2023), Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing, Blood Advances 7(5): 812-827.
- Zouwen, B. van der; Koster, E.A.S.; Borne, P.A. von dem; Oosten, L.E.M.; Roza-Scholten, M.W.I.; Snijders, T.J.F.; Lammeren, D. van; Balen, P. van; Marijt, W.A.F.; Veelken, H.; Falkenburg, J.H.F.; Wreede, L.C. de & Halkes, C.J.M. (2023), Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients, Annals of Hematology 102.
- Struckman, N.; Jong, R. de; Lee, D. van der; Veelen, P. van; Falkenburg, J.H.F. & Griffioen, M. (2023), RUNX1 NEOANTIGENS AS TARGETS FOR TCR GENE THERAPY IN ACUTE MYELOID LEUKEMIA, Human Gene Therapy 34(21-22): A24-A24.
- Luk, S.J.; Schoppmeyer, R.; Ijsselsteijn, M.E.; Somarakis, A.; Acem, I.; Remst, D.F.G.; Cox, D.T.; Bergen, C.A.M. van; Briaire-de Bruijn, I.; Grönloh, M.L.B.; Meer, W.J. van der; Hawinkels, L.J.A.C.; Koning, R.I.; Bos, E.; Bovée, J.V.M.G.; Miranda, N.F.C.C. de; Szuhai, K.; Buul, J.D. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation, Cancer Immunology Research 11(11): 1480-1492.
- Koster, E.A.S.; Bonneville, E.F.; Borne, P.A.V.; Balen, P. van; Marijt, E.W.A.; Tjon, J.M.L.; Snijders, T.J.F.; Lammeren, D. van; Veelken, H.; Putter, H.; Falkenburg, J.H.F.; Halkes, C.J.M. & Wreede, L.C. de (2023), Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion, Frontiers in Immunology 14.
- Wachsmann, T.L.A.; Meeuwsen, M.H.; Remst, D.F.G.; Buchner, K.; Wouters, A.K.; Hagedoorn, R.S.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma, Blood Advances 7(20): 6178-6183.
- Kester, M.; Klobuch, S.; Balen, P. van; Klerk, W. de; Ru, A. de; Jedema, I.; Veelen, P. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), Forward or reversed binding of peptides within the HLA-DP peptidome is mainly determined by the HLA-DPB1 allele but with a key role for the HLA-DPA1 chain, HLA: Immune Response Genetics 101(4): 328-328.
- Pool, E.S.; Kooy-Winkelaar, Y.; Unen, V. van; Falkenburg, J.H.F.; Koning, F.; Heemskerk, M.H.M. & Tjon, J.M.L. (2023), Mass cytometric analysis unveils a disease-specific immune cell network in the bone marrow in acquired aplastic anemia, Frontiers in Immunology 14.
- Kittissares, K.; Crivello, P.; Walther, T.; Mohammaddokht, M.; Bolaños, T.A.; Metzing, M.F.; Betke, L.; Lux, D.; Bracht, T.; Turki, A.T.; Eisenacher, M.; Horn, P.A.; Köster, J.; Falkenburg, J.H.F.; Griffioen, M.; Sitek, B.; Fleischhauer, K. & Bolaños, E.A. (2023), MEMORY CD4+T CELLS EFFICIENTLY RECOGNIZE DIVERGENT HLA-DP IMMUNOPEPTIDOMES RELEVANT IN ALLOGENEIC HCT, Bone Marrow Transplantation 58(SUPP1): 70-71.
- Kittissares, K.; Crivello, P.; Walther, T.; Mohammaddokht, M.; Bolaños, T.A.; Metzing, M.F.; Betke, L.; Lux, D.; Bracht, T.; Turki, A.T.; Eisenacher, M.; Horn, P.A.; Köster, J.; Falkenburg, J.H.F.; Griffioen, M.; Sitek, B.; Fleischhauer, K. & Bolaños, E.A. (2023), Memory CD4+T cells efficiently recognize divergent HLA-DP immunopeptidomes relevant in allogeneic hematopoietic cell transplantation, HLA: Immune Response Genetics 101(4): 353-353.
- Huisman, W.; Gier, M. de; Hageman, L.; Shomuradova, A.S.; Leboux, D.A.T.; Amsen, D.; Falkenburg, J.H.F. & Jedema, I. (2022), Amino acids at position 5 in the peptide/MHC binding region of a public virus-specific TCR are completely inter-changeable without loss of function, European Journal of Immunology 52(11): 1819-1828.
- Kittisares, K.; Eleftheriou, M.; Betke, L.; Griffioen, M.; Horn, P.A.; Falkenburg, J.H.F.; Fleischhauer, K. & Arrieta-Bolanos, E. (2022), Immunopeptidome deregulation differentially affects naive and memory CD4+T-cell alloreactive responses against minor histocompatibility antigens, HLA: Immune Response Genetics 99(5): 475-476.
- Meeuwsen, M.H.; Wouters, A.K.; Wachsmann, T.L.A.; Hagedoorn, R.S.; Kester, M.G.D.; Remst, D.F.G.; Steen, D.M. van der; Ru, A.H. de; Hees, E.P. van; Griffioen, M.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain, Blood 140: 4498-4499.
- Pothast, C.R.; Hofsink, Q.; Haggenburg, S.; Bhoekhan, M.; Haverkate, N.J.E.; Dijkland, R.C.; Dijk, K. van; Falkenburg, F.J.H.; Broers, A.E.C.; Doesum, J. van; Binnendijk, R.S. van; Hartog, G. den; Burger, J.A.; Bouhuijs, J.H.; Lissenberg-Witte, B.I.; Smits, G.P.; Wouters, D.; Leeuwen, E.M.M. van; Bontkes, H.J.; Kootstra, N.A.; Zweegman, S.; Kater, A.P.; Groen, K.; Meerten, T. van; Mutsaers, P.G.N.J.; Beaumont, T.; Gils, M.J. van; Goorhuis, A.; Hazenberg, M.D.; Nijhof, I.S.; Heemskerk, M.H.M. & Rutten, C.E. (2022), Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination, Blood 140: 1957-1959.
- Pothast, C.R.; Hofsink, Q.; Haggenburg, S.; Michel, B.S.; Haverkate, N.J.E.; Dijkland, R.C.; Dijk, K. van; Falkenburg, F.J.H.; Broers, A.E.C.; Doesum, J. van; Binnendijk, R.S. van; Hartog, G. den; Burger, J.A.; Bouhuijs, J.H.; Lissenberg-Witte, B.I.; Smits, G.P.; Wouters, D.; Leeuwen, E.M.M. van; Bontkes, H.J.; Kootstra, N.A.; Zweegman, S.; Kater, A.P.; Groen, K.; Meerten, T. van; Mutsaers, P.G.N.J.; Beaumont, T.; Gils, M.J. van; Goorhuis, A.; Hazenberg, M.D.; Nijhof, I.S.; Heemskerk, M.H.M. & Rutten, C.E. (2022), Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies, Blood 140: 8347-8349.
- Huisman, W.; Hageman, L.; Leboux, D.A.T.; Khmelevskaya, A.; Efimov, G.A.; Roex, M.C.J.; Amsen, D.; Falkenburg, J.H.F. & Jedema, I. (2022), Public T-Cell Receptors (TCRs) revisited by analysis of the magnitude of identical and highly-similar TCRs in virus-specific T-Cell repertoires of healthy individuals, Frontiers in Immunology 13.
- Eleftheriou, M.; Kittisares, K.; Walther, T.; Betke, L.; Griffioen, M.; Horn, P.A.; Falkenburg, J.H.F.; Fleischhauer, K. & Arrieta-Bolanos, E. (2022), T-cell receptor cross-reactivity against minor histocompatibility antigens and permissively mismatched HLA-DP reveals distinct features for DPB1*02:01 and*04:02, HLA: Immune Response Genetics 99(5): 428-428.
- Koutsoumpli, G.; Lee, D.I. van der; Groenland, N.C.; Honders, M.W.; Jong, R.C.M. de; Hagedoorn, R.S.; Veelken, H.; Veelen, P.A. van; Lock, D.; Heemskerk, M.H.M.; Falkenburg, J.H.F.; Johnston, I. & Griffioen, M. (2022), Immunotherapy Targeting Mutant Nucleophosmin-1 on Acute Myeloid Leukemia, Blood 140: 10243-10244.
- Arrieta-Bolanos, T.; Crivello, P.; Pietz, T.; Lindemann, M.; Horn, P.A.; Falkenburg, J.H.F.; Arrieta-Bolanos, E. & Fleischhauer, K. (2022), Towards the identification of hematopoietic tissue-specific T-cell receptors alloreactive to HLA-DPB1, HLA: Immune Response Genetics 99(5): 428-429.
- Amerongen, R.A. van; Hagedoorn, R.S.; Remst, D.F.G.; Assendelft, D.C.; Steen, D.M. van der; Wouters, A.K.; Meent, M. van de; Kester, M.G.D.; Ru, A.H. de; Griffioen, M.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma, Journal for ImmunoTherapy of Cancer 10(6).
- Meeuwsen, M.H.; Wouters, A.K.; Wachsmann, T.L.A.; Hagedoorn, R.S.; Remst, D.F.G.; Kester, M.G.D.; Steen, D.M. van der; Ru, A.H. de; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma, Blood 140: 10292-10293.
- Struckman, N.E.; Klobuch, S.; Kester, M.G.D.; Klerk, W. de; Ru, A.H. de; Heemskerk, M.H.M.; Veelen, P.A. van; Balen, P. van; Falkenburg, J.H.F. & Griffioen, M. (2022), Immunotherapy By Targeting CD45 in Mismatched HLA-DP to Treat Patients after Allogeneic Stem Cell Transplantation, Blood 140: 4545-4546.
- Meeuwsen, M.H.; Wouters, A.K.; Jahn, L.; Hagedoorn, R.S.; Kester, M.G.D.; Remst, D.F.G.; Morton, L.T.; Steen, D.M. van der; Kweekel, C.; Ru, A.H. de; Griffioen, M.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy, Molecular Therapy 30(2): 564-578.
- Laghmouchi, A.; Kester, M.G.D.; Hoogstraten, C.; Hageman, L.; Klerk, W. de; Huisman, W.; Koster, E.A.S.; Ru, A.H. de; Balen, P. van; Klobuch, S.; Veelen, P.A. van; Falkenburg, J.H.F. & Jedema, I. (2022), Promiscuity of peptides presented in HLA-DP molecules from different immunogenicity groups is associated with T-cell cross-reactivity, Frontiers in Immunology 13.
- Wachsmann, T.L.A.; Wouters, A.K.; Remst, D.F.G.; Hagedoorn, R.S.; Meeuwsen, M.H.; Diest, E. van; Leusen, J.; Kuball, J.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure, OncoImmunology 11(1).
- Pothast, C.R.; Dijkland, R.C.; Thaler, M.; Hagedoorn, R.S.; Kester, M.G.D.; Wouters, A.K.; Hiemstra, P.S.; Hemert, M.J. van; Gras, S.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross- reactive CMV- specific T cells, eLife 11.
- Pothast, C.R.; Dijkland, R.C.; Thaler, M.; Hagedoorn, R.S.; Kester, M.G.D.; Wouters, A.K.; Hiemstra, P.S.; Hemert, M.J. van; Gras, S.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), Sars-Cov-2-Specific CD4+ and CD8+ T Cell Responses Can Originate from Cross-Reactive CMV-Specific T Cells, Blood 140: 2631-2632.
- Meeuwsen, M.H.; Wouters, A.K.; Hagedoorn, R.S.; Kester, M.G.D.; Remst, D.F.G.; Steen, D.M. van der; Ru, A. de; Veelen, P.A. van; Rossjohn, J.; Gras, S.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), Cutting edge, The Journal of Immunology 208(8): 1851-1856.
- Fuchs, K.J.; Honders, M.W.; Meent, M. van de; Khatri, I.; Koster, E.A.S.; Bergen, C.A.M. van; Akker, E.B. van den; Halkes, C.J.M.; Falkenburg, J.H.F. & Griffioen, M. (2022), Large Scale Identification and Validation of 85 New HLA Class I-Restricted Minor Histocompatibility Antigens for Immune Monitoring and Modulation after Allogeneic Stem Cell Transplantation, Blood 140: 10196-10197.
- Pool, E.S.; Kooy-Winkelaar, Y.; Unen, V. van; Falkenburg, J.H.F.; Koning, F.; Heemskerk, M.H.M. & Tjon, J.M.L. (2022), High-Dimensional Mass Cytometric Analysis of the Bone Marrow Compartment Identifies a Disease-Specific Immune Cell Network in Aplastic Anemia, Blood 140.
- Morton, L.T.; Wachsmann, T.L.A.; Meeuwsen, M.H.; Wouters, A.K.; Remst, D.F.G.; Loenen, M.M. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion, Journal for ImmunoTherapy of Cancer 10(3).
- Klobuch, S, Heemskerk, MHM, Falkenburg, JHF, Balen, P van, Pothast & CR (2022), Human T cells recognize HLA-DP bound peptides in two orientations, Proceedings of the National Academy of Sciences of the United States of America 119(49).
- Huisman, W.; Gille, I.; Maarel, L.E. van der; Hageman, L.; Morton, L.T.; Jong, R.C.M. de; Heemskerk, M.H.M.; Amsen, D.; Falkenburg, J.H.F. & Jedema, I. (2022), Identification of functional HLA-A*01:01-restricted Epstein-Barr latent membrane protein 2-Specific T-Cell receptors, The Journal of Infectious Diseases 226(5): 833-842.
- Einsele, H.; Briones, J.; Ciceri, F.; Cadenas, I.G.; Falkenburg, F.; Bolanos, N.; Heemskerk, H.M.M.; Houot, R.; Hudecek, M.; Locatelli, F.; Morgan, K.; Morris, E.C.; O'Dwyer, M.; Sierra, J.G.; Brink, M. van den & Loosdrecht, A.A. van de (2021), The EHA research roadmap: immune-based therapies for hematological malignancies, HemaSphere 5(10).
- Rooij, M.A.J. de; Steen, D.M.; Remst, D.; Wouters, A.; Kester, M.G.D.; Hagedoorn, R.S.; Veelen, P.A. van; Verdegaal, E.M.E.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2021), A library of novel cancer testis specific T-cell receptors for T-cell receptor gene therapy, Journal for ImmunoTherapy of Cancer 9: A2-A3.
- Struckman, N.; Jong, R. de; Lee, D. van der; Veelen, P. van; Falkenburg, J.H.F. & Griffioen, M. (2021), Mutant RUNX1 may encode relevant neoantigens for immunotherapy in acute myeloid leukemia, European Journal of Immunology 51: 404-404.
- Lee, D.I. van der; Koutsoumpli, G.; Reijmers, R.M.; Honders, M.W.; Jong, R.C.M. de; Remst, D.F.G.; Wachsmann, T.L.A.; Hagedoorn, R.S.; Franken, K.L.M.C.; Kester, M.G.D.; Harber, K.J.; Roelofsen, L.M.; Schouten, A.M.; Mulder, A.; Drijfhout, J.W.; Veelken, H.; Veelen, P.A. van; Heemskerk, M.H.M.; Falkenburg, J.H.F. & Griffioen, M. (2021), An HLA-A*11:01-binding neoantigen from mutated NPM1 as target for TCR gene therapy in AML, Cancers 13(21).
- Fuchs, K.J.; Meent, M. van de; Honders, M.W.; Bergen, C.A.M. van; Falkenburg, J.H.F. & Griffioen, M. (2021), Expanding the repertoire of HLA class I-restricted minor histocompatibility antigens for immune monitoring and modulation after allogeneic stem cell transplantation, European Journal of Immunology 51: 206-206.
- Sluijs, J.V. van der; Ens, D. van; Thordardottir, S.; Vodegel, D.; Hermens, I.; Waart, A.B. van der; Falkenburg, J.H.F.; Kester, M.G.D.; Rink, I. de; Heemskerk, M.H.M.; Borst, J.; Schaap, N.P.M.; Jansen, J.H.; Xiao, Y.L.; Dolstra, H. & Hobo, W. (2021), Clinically applicable CD34(+)-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses, Cancer Immunology, Immunotherapy 70.
- Huisman, W.; Leboux, D.A.T.; Maarel, L.E. van der; Hageman, L.; Amsen, D.; Falkenburg, J.H.F. & Jedema, I. (2021), Magnitude of off-target allo-HLA reactivity by third-party donor-derived virus-specific T cells is dictated by HLA-restriction, Frontiers in Immunology 12.
- Meurer, T.; Crivello, P.; Metzing, M.; Kester, M.; Megger, D.A.; Chen, W.Q.; Veelen, P.A. van; Balen, P. van; Westendorf, A.M.; Homa, G.; Layer, S.E.; Turki, A.T.; Griffioen, M.; Horn, P.A.; Sitek, B.; Beelen, D.W.; Falkenburg, J.H.F.; Arrieta-Bolanos, E. & Fleischhauer, K. (2021), Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM, Blood 137(7): 923-928.
- Wiersum-Osselton, J.C.; Slomp, J.; Falkenburg, J.H.F.; Geltink, T.; Duijnhoven, H.L.P. van; Netelenbos, T. & Schipperus, M.R. (2021), Guideline development for prevention of transfusion-associated graft-versus-host disease, British Journal of Haematology 195(5).
- Roex, M.C.J.; Wijnands, C.; Veld, S.A.J.; Egmond, E. van; Bogers, L.; Zwaginga, J.J.; Netelenbos, T.; Borne, P.A. von dem; Veelken, H.; Halkes, C.J.M.; Falkenburg, J.H.F. & Jedema, I. (2021), Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation, Cytotherapy 23(1): 46-56.
- Einsele, H.; Briones, J.; Ciceri, F.; Garcia-Cadenas, I.; Falkenburg, F.; Bolanos, N.; Heemskerk, H.M.M.; Houot, R.; Hudecek, M.; Locatelli, F.; Morgan, K.; Morris, C.E.; O'Dwyer, M.; Gil, J.S.; Brink, M. van den & Loosdrecht, A.A. van de (2020), Immune-based therapies for hematological malignancies: an update by the EHA SWG on immunotherapy of hematological malignancies, HemaSphere 4(4).
- Roex, M.C.J.; Balen, P. van; Germeroth, L.; Hageman, L.; Egmond, E. van; Veld, S.A.J.; Hoogstraten, C.; Liempt, E. van; Zwaginga, J.J.; Wreede, L.C. de; Meij, P.; Vossen, A.C.T.M.; Danhof, S.; Einsele, H.; Schaafsma, M.R.; Veelken, H.; Halkes, C.J.M.; Jedema, I. & Falkenburg, J.H.F. (2020), Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study, Leukemia 34(3): 831-844.
- Balen, P. van; Jedema, I.; Loenen, M.M. van; Boer, R. de; Egmond, H.M. van; Hagedoorn, R.S.; Hoogstaten, C.; Veld, S.A.J.; Hageman, L.; Liempt, P.A.G. van; Zwaginga, J.J.; Meij, P.; Veelken, H.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2020), HA-1H T-cell receptor gene transfer to redirect virus-specific T cells for treatment of hematological malignancies after allogeneic stem cell transplantation, Frontiers in Immunology 11.
- Balen, P. van; Kester, M.G.D.; Klerk, W. de; Crivello, P.; Arrieta-Bolanos, E.; Ru, A.H. de; Jedema, I.; Mohammed, Y.; Heemskerk, M.H.M.; Fleischhauer, K.; Veelen, P.A. van & Falkenburg, J.H.F. (2020), Immunopeptidome analysis of HLA-DPB1 allelic variants reveals new functional hierarchies, The Journal of Immunology 204(12): 3273-3282.
- Rooij, M.A.J. de; Steen, D.M. van der; Remst, D.; Wouters, A.; Meent, M. van der; Hagedoorn, R.S.; Kester, M.G.D.; Veelen, P.A. van; Falkenburg, F.J.H. & Heemskerk, M.H.M. (2020), High-affinity TCRS specific for cancer testis antigens as a therapy for multiple myeloma and solid tumors, Journal for ImmunoTherapy of Cancer 8: A49-A49.
- Morton, L.T.; Reijmers, R.M.; Wouters, A.K.; Kweekel, C.; Remst, D.F.G.; Pothast, C.R.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2020), Simultaneous deletion of endogenous TCR alpha beta for TCR gene therapy creates an improved and safe cellular therapeutic, Molecular Therapy 28(1): 64-74.
- Fuchs, K.J.; Honders, M.W.; Meijden, E.D. van der; Adriaans, A.E.; Lee, D.I. van der; Pont, M.J.; Monajemi, R.; Kielbasa, S.M.; Hoen, P.A.C. 't; Bergen, C.A.M. van; Falkenburg, J.H.F. & Griffioen, M. (2020), Optimized whole genome association scanning for discovery of HLA class I-restricted minor histocompatibility antigens, Frontiers in Immunology 11.
- Roex, M.C.J.; Hageman, L.; Veld, S.A.J.; Egmond, E. van; Hoogstraten, C.; Stemberger, C.; Germeroth, L.; Einsele, H.; Falkenburg, J.H.F. & Jedema, I. (2020), A minority of T cells recognizing tumor-associated antigens presented in self-HLA can provoke antitumor reactivity, Blood 136(4): 455-467.
- Laghmouchi, A.; Hoogstraten, C.; Falkenburg, J.H.F. & Jedema, I. (2020), Priming of allo-HLA-DP-specific reactivity from the naive T cell compartment is not exclusively mediated by professional antigen-presenting cells, Biology of Blood and Marrow Transplantation 26(7): 1257-1265.
- Laghmouchi, A.; Hoogstraten, C.; Falkenburg, J.H.F. & Jedema, I. (2020), Long-term in vitro persistence of magnetic properties after magnetic bead-based cell separation of T cells, Scandinavian Journal of Immunology 92(3).
- Kremer, A.N.; Bausenwein, J.; Lurvink, E.; Kremer, A.E.; Rutten, C.E.; Bergen, C.A.M. van; Kretschmann, S.; Meijden, E. van der; Honders, M.W.; Mazzeo, D.; Watts, C.; Mackensen, A.; Falkenburg, J.H.F. & Griffioen, M. (2020), Discovery and differential processing of HLA class II-restricted minor histocompatibility antigen LB-PIP4K2A-1S and its allelic variant by asparagine endopeptidase, Frontiers in Immunology 11.
- Meurer, T.; Crivello, P.; Metzing, M.; Kester, M.; Megger, D.; Chen, W.Q.; Veelen, P.A. van; Balen, P. van; Westendorf, A.M.; Homa, G.; Niersch, J.; Turki, A.T.; Griffioen, M.; Horn, P.A.; Sitek, B.; Beelen, D.W.; Falkenburg, J.H.F.; Arrieta-Bolanos, E. & Fleischhauerl, K. (2020), UNRAVELING THE DETERMINANTS OF ALLOREACTIVITY IN HUMANS: HLA-DP AS A MODEL FOR IMMUNITY AND TRANSPLANTATION, HLA: Immune Response Genetics 95(4): 275-275.
- Crivello, P.; Meurer, T.; Megger, D.; Arrieta-Bolaños, E.; Metzing, M.; Chen, W.Q.; Kester, M.; Balen, P. van; Falkenburg, J.H.F.; Sitek, B. & Fleischhauer, K. (2019), IMPACT OF THE AMINO ACID POLYMORPHISM AT POSITION 84 AND HLA-DM ON THE IMMUNOPEPTIDOME OF HLA-DPB1, HLA: Immune Response Genetics 93(5): 280-281.
- Arrieta-Bolanos, E.; Mohamaddokht, M.; Meurer, T.; Crivello, P.; Turki, A.; Horn, P.A.; Beelen, D.W.; Falkenburg, J.H.F. & Fleischhauer, K. (2019), Relative contribution of naive and memory T cells to alloreactivity in hematopoietic stem cell transplantation, Oncology Research and Treatment 42: 233-233.
- Lee, D.I. van der; Reijmers, R.M.; Honders, M.W.; Hagedoorn, R.S.; Jong, R.M. de; Kester, M.G.D.; Steen, D.M. van der; Ru, A.H. de; Kweekel, C.; Jedema, I.; Veelken, H.; Heemskerk, M.M.; Veelen, P.A. van; Falkenburg, J.H.F. & Griffioen, M. (2019), Mutated NPM1 as target for immunotherapy of acute myeloid leukemia, Cancer Immunology Research 7(2).
- Huisman, W.; Gille, I.; Maarel, L.E. van der; Hageman, L.; Jong, R.C.M. de; Amsen, D.; Falkenburg, F. & Jedema, I. (2019), The First Functional HLA-a*01:01-Restricted EBV-LMP2-Specific T-Cell Receptors for TCR Gene Therapy of Patients with EBV-Associated Type II/III Malignancies, Blood 134.
- Huisman, W.; Leboux, D.A.T.; Maarel, L.E. van der; Hageman, L.; Amsen, D.; Falkenburg, F. & Jedema, I. (2019), Off-Target HLA Cross-Reactivity By (Third Party) Virus-Specific T Cells Is Surprisingly Affected By HLA Restriction and HLA Background but Not By Virus Specificity, Blood 134.
- Arrieta-Bolanos, E.; Metzing, M.; Homa, G.; Meurer, T.; Crivello, P.; Turki, A.; Horn, P.A.; Falkenburg, J.H.F. & Fleischhauer, K. (2019), HLA-DM-MEDIATED PEPTIDE EDITING IMPACTS T CELL RECEPTOR DIVERSITY AGAINST PERMISSIVE HLA-DPB1 MISMATCHES, HLA: Immune Response Genetics 93(5): 258-259.
- Metzing, M.; Crivello, P.; Meurer, T.; Kester, M.G.D.; Megger, D.; Chen, W.Q.; Balen, P. van; Griffioen, M.; Horn, P.A.; Sitek, B.; Falkenburg, J.H.F.; Arrieta-Bolanos, E. & Fleischhauer, K. (2019), HLA-DM Mediates Permissiveness of HLA-DPB1 T Cell Epitope Mismatches in Unrelated HCT, Blood 134.
- Arrieta-Bolanos, E.; Crivello, P.; Meurer, T.; Metzing, M.; Griffioen, M.; Horn, P.A.; Falkenburg, J.H.F. & Fleischhauer, K. (2019), HLA-DM-MEDIATED PEPTIDE EDITING REGULATES SELF-HLA-DP RESTRICTED T-CELL ALLOREACTIVITY TO MINOR HISTOCOMPATIBILITY ANTIGENS, HLA: Immune Response Genetics 93(5): 273-274.
- Morton, L.T.; Wouters, A.K.; Remst, D.F.; Hagedoorn, R.S.; Loenen, M.M. van; Boer, R. de; Falkenberg, J.H.F. & Heemskerk, M.H.M. (2019), Effective rerouting of NK cell cytotoxicity against B-cell malignancies upon TCR gene transfer, Cancer Immunology Research 7(2).
- Arrieta-Bolanos, E.; Meurer, T.; Mohamaddokht, M.; Metzing, M.; Balen, P. van; Horn, P.A.; Falkenburg, J.H.F.; Fleischhauer, K. & Crivello, P. (2019), PEPTIDE REPERTOIRE OR EXPRESSION LEVELS: WHAT IS THE DRIVING FORCE FOR T CELL ALLOREACTIVITY TO HLA-DP?, HLA: Immune Response Genetics 93(5): 278-278.
- Lee, D.I. van der; Reijmers, R.M.; Honders, M.W.; Hagedoorn, R.S.; Jong, R.C.M. de; Kester, M.G.D.; Steen, D.M. van der; Ru, A.H. de; Kweekel, C.; Bijen, H.M.; Jedema, I.; Veelken, H.; Veelen, P.A. van; Heemskerk, M.H.M.; Falkenburg, J.H.F. & Griffioen, M. (2019), Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia, Journal of Clinical Investigation 129(2): 774-785.
- Loeff, F.C.; Rijs, K.; Egmond, E.H.M. van; Zoutman, W.H.; Qiao, X.H.; Kroes, W.G.M.; Veld, S.A.J.; Griffioen, M.; Vermeer, M.H.; Neefjes, J.; Falkenburg, J.H.F.; Halkes, C.J.M. & Jedema, I. (2019), Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression, American Journal of Hematology 94(1): 93-102.
- Pont, M.J.; Oostvogels, R.; Bergen, C.A.M. van; Meijden, E. van der; Honders, M.W.; Bliss, S.; Jongsma, M.L.M.; Lokhorst, H.M.; Falkenburg, J.H.F.; Mutis, T.; Griffioen, M. & Spaapen, R.M. (2019), T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells, Cancer Immunology Research 7(5): 797-804.
- Arrieta-Bolanos E, Mohamaddokht M, Horn PA, Falkenburg JHF & Fleischhauer K (2019), RELATIVE CONTRIBUTION OF NAIVE AND MEMORY T CELLS TO ALLOREACTIVITY AGAINST MAJOR OR MINOR HISTOCOMPATIBILITY ANTIGENS, Hla 93(5): 272-273.
- Crivello, P.; Ahci, M.; Maassen, F.; Wossidlo, N.; Arrieta-Bolanos, E.; Heinold, A.; Lange, V.; Falkenburg, J.H.F.; Horn, P.A.; Fleischhauer, K. & Heinrichs, S. (2019), Multiple Knockout of Classical HLA Class II beta-Chains by CRISPR/Cas9 Genome Editing Driven by a Single Guide RNA, Journal of Immunology 202(6): 1895-1903.
- Loeff, F.C.; Egmond, E.H.M. van; Moes, D.J.A.R.; Wijnands, C.; Borne, P.A. von dem; Veelken, H.; Falkenburg, J.H.F.; Jedema, I. & Halkes, C.J.M. (2019), Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft, Transplant Immunology 57.
- Kierkels, G.J.J.; Scheper, W.; Meringa, A.D.; Johanna, I.; Beringer, D.X.; Janssen, A.; Schiffler, M.; Aarts-Riemens, T.; Kramer, L.; Straetemans, T.; Heijhuurs, S.; Leusen, J.H.W.; San Jose, E.; Fuchs, K.; Griffioen, M.; Falkenburg, J.H.; Bongiovanni, L.; Bruin, A. de; Vargas-Diaz, D.; Altelaar, M.; Heck, A.J.R.; Shultz, L.D.; Ishikawa, F.; Nishimura, M.I.; Sebestyen, Z. & Kuball, J. (2019), Identification of a tumor-specific allo-HLA-restricted gamma delta TCR, Blood Advances 3(19): 2870-2882.
- Kalin, B.; Borg, M. ter; Wijers, R.; Somers, J.A.E.; Holt, B. van der; Bergen, C.A.M. van; Petersen, E.J.; Kuball, J.; Meijer, E.; Schaap, N.P.M.; Zeerleder, S.S.; Broers, A.E.; Braakman, E.; Falkenburg, J.H.F.; Lamers, C.H.J. & Cornelissen, J.J. (2019), Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance.
- Noviello, M.; Manfredi, F.; Ruggiero, E.; Perini, T.; Oliveira, G.; Cortesi, F.; Simone, P. de; Toffalori, C.; Gambacorta, V.; Greco, R.; Peccatori, J.; Casucci, M.; Casorati, G.; Dellabona, P.; Onozawa, M.; Teshima, T.; Griffioen, M.; Halkes, C.J.M.; Falkenburg, J.H.F.; Stolzel, F.; Altmann, H.; Bornhauser, M.; Waterhouse, M.; Zeiser, R.; Finke, J.; Cieri, N.; Bondanza, A.; Vago, L.; Ciceri, F. & Bonini, C. (2019), Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT, Nature Communications 10.
- Laghmouchi, A.; Hoogstraten, C.; Balen, P. van; Falkenburg, J.H.F. & Jedema, I. (2019), The allogeneic HLA-DP-restricted T-cell repertoire provoked by allogeneic dendritic cells contains T cells that show restricted recognition of hematopoietic cells including primary malignant cells, Haematologica 104(1): 197-206.
- Falkenburg, F.; Ruggiero, E.; Bonini, C.; Porter, D.; Miller, J.; Malard, F.; Mohty, M.; Kroger, N. & Kolb, H.J. (2019), Prevention and treatment of relapse after stem cell transplantation by cellular therapies, Bone Marrow Transplantation 54(1): 26-34.
- Arrieta-Bolanos, E.; Crivello, P.; Metzing, M.; Meurer, T.; Ahci, M.; Rytlewski, J.; Vignali, M.; Yusko, E.; Balen, P. van; Horn, P.A.; Falkenburg, J.H.F. & Fleischhauer, K. (2018), Alloreactive T Cell Receptor Diversity against Structurally Similar or Dissimilar HLA-DP Antigens Assessed by Deep Sequencing, Frontiers in Immunology 9.
- Balen, P. van; Kester, M.G.D.; Crivello, P.; Ru, A.H. de; Klerk, W. de; Meent, M. van de; Jedema, I.; Fleischhauer, K.; Falkenburg, J.H.F. & Veelen, P.A. van (2018), Motifs of peptides binding in HLA-DP and their relation with T-cell epitope groups relevant in stem cell transplantation, Bone Marrow Transplantation 53: 64-65.
- Hutten, T.J.A.; Norde, W.J.; Woestenenk, R.; Wang, R.C.; Maas, F.; Kester, M.; Falkenburg, J.H.F.; Berglund, S.; Luznik, L.; Jansen, J.H.; Schaap, N.; Dolstra, H. & Hobo, W. (2018), Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8(+) T Cells During Relapse after Allogeneic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation 24(4): 666-677.
- Roex, M.C.J.; Balen, P. van; Germeroth, L.; Hageman, L.; Egmond, E. van; Veld, S.A.J.; Hoogstraten, C.; Liempt, E. van; Zwaginga, J.J.; Wreede, L.C. de; Einsele, H.; Veelken, H.; Halkes, C.J.M.; Jedema, I. & Falkenburg, J.H.F. (2018), Prophylactic Infusion of Multi-Antigen Specific T-Cell Products to Prevent Complications after T Cell Depleted Allogeneic Stem Cell Transplantation - a Phase I/II Study, Blood 132.
- Balen, P. van; Zouwen, B. van der; Kruisselbrink, A.B.; Eefting, M.; Szuhai, K.; Jordanova, E.S.; Falkenburg, J.H.F. & Jedema, I. (2018), Tissue damage in the skin caused by myeloablative conditioning before allogeneic stem cell transplantation results in dermal recruitment of macrophages without inflammation, Bone Marrow Transplantation 53: 459-459.
- Huisman, W.; Leboux, D.A.T.; Maarel, L.E. van der; Hageman, L.; Amsen, D.; Falkenburg, J.H.F. & Jedema, I. (2018), The Scope of Allo-HLA Cross-Reactivity By (Third Party) Virus Specific T Cells Is Surprisingly Affected By HLA Restriction Rather Than Virus Specificity, Blood 132.
- Jedema, I.; Balen, P. van; Halkes, C.J.M.; Egmond, E.H.M. van; Liempt, E.A.G. van; Veld, S.A.J.; Hoogstraten, C.; Meij, P.; Kersting, S.; Zwaginga, J.J.; Rauser, G.; Assenmacher, M. & Falkenburg, J.H.F. (2018), Phase I/II clinical trial demonstrates feasibility, safety and effectivity of CMV-pp65-specific donor T-cells for the treatment of refractory CMV reactivation after allogeneic stem cell transplantation, Bone Marrow Transplantation 53: 45-45.
- Koster, E.A.S.; Wreede, L.C. de; Wallet-Malicka, S.; Bogers, L.; Balen, P. van; Marijt, W.; Jedema, I.; Borne, P.V.D.; Veelken, H.; Falkenburg, J.H.F. & Halkes, C.J.M. (2018), Patient Bone Marrow Chimerism at Time of Donor Lymphocyte Infusion Predicts Development of Graft Versus Host Disease, Blood 132.
- Koster, E.A.S.; Wreede, L.C. de; Borne, P.A. von dem; Marijt, E.W.A.; Balen, P. van; Wallet-Malicka, S.M.; Bogers, E.J.M.; Veelken, J.H.; Halkes, C.J.M. & Falkenburg, J.H.F. (2018), Multi-state modelling to evaluate strategy of scheduled prophylactic donor lymphocyte infusions after T-cell depleted transplantation following low-toxicity conditioning for elderly patients with high risk leukemia, Bone Marrow Transplantation 53: 433-435.
- Huisman, W.; Maarel, L.E. van der; Hageman, L.; Jong, R.C.M. de; Amsen, D.; Falkenburg, J.H.F. & Jedema, I. (2018), Isolation and Validation of the First Functional HLA-a*01:01 Restricted EBV-LMP2 Specific T Cells for Treatment of EBV Associated Type II/III Lymphomas, Blood 132.
- Loeff, F.C.; Falkenburg, J.H.F.; Hageman, L.; Huisman, W.; Veld, S.A.J.; Egmond, H.M.E. van; Meent, M. van de; Borne, P.A. von dem; Veelken, H.; Halkes, C.J.M. & Jedema, I. (2018), High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor(-)/CD52(-) T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell-Depleted Allogeneic Stem Cell Transplantation, Journal of Immunology 200(6): 2199-2208.
- Meurer, T.; Bolanos, E.A.; Metzing, M.; Langer, M.; Balen, P. van; Falkenburg, F.; Beelen, D.W.; Horn, P.A.; Fleischhauer, K. & Crivello, P. (2018), DISSECTING GENETIC CONTROL OF HLA-DPB1 EXPRESSION AND ITS RELATION TO STRUCTURAL MISMATCH MODELS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION, Hla 91(5): 339-339.
- Meurer, T.; Arrieta-Bolanos, E.; Metzing, M.; Langer, M.M.; Balen, P. van; Falkenburg, J.H.F.; Beelen, D.W.; Horn, P.A.; Fleischhauer, K. & Crivello, P. (2018), Dissecting Genetic Control of HLA-DPB1 Expression and Its Relation to Structural Mismatch Models in Hematopoietic Stem Cell Transplantation, Frontiers in Immunology 9.
- Meurer, T.; Arrieta-Bolanos, E.; Metzing, M.; Langer, M.M.; Balen, P. van; Falkenburg, J.H.F.; Beelen, D.W.; Horn, P.A.; Fleischhauer, K. & Crivello, P. (2018), Dissecting genetic control of HLA-DPB1 expression and its relation to structural mismatch models in hematopoietic stem cell transplantation, Bone Marrow Transplantation 53: 742-742.
- Roex, M.C.J.; Hageman, L.; Egmond, E. van; Veld, S.A.J.; Hoogstraten, C.; Germeroth, L.; Falkenburg, J.H.F. & Jedema, I. (2018), A minority of tumor associated antigen specific T cells restricted to self-HLA alleles is of sufficient avidity to recognize overexpressed endogenously processed antigen, Bone Marrow Transplantation 53: 43-44.
- Balen, P. van; Zouwen, B. van der; Kruisselbrink, A.B.; Eefting, M.; Szuhai, K.; Jordanova, E.S.; Falkenburg, J.H.F. & Jedema, I. (2018), Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-cell Interaction, Frontiers in Immunology 9.
- Roex, M.C.J.; Hageman, L.; Heemskerk, M.; Veld, S.A.J.; Liempt, E. van; Kester, M.G.D.; Germeroth, L.; Stemberger, C.; Falkenburg, J.H.F. & Jedema, I. (2018), The simultaneous isolation of multiple high and low frequent T-cell populations from donor peripheral blood mononuclear cells using the major histocompatibility complex I-Streptamer isolation technology, Cytotherapy 20(4): 543-555.
- Heiden, P. van der; Marijt, E.; Falkenburg, F. & Jedema, I. (2018), Control of Cytomegalovirus Viremia after Allogeneic Stem Cell Transplantation: A Review on CMV-Specific T Cell Reconstitution, Biology of Blood and Marrow Transplantation 24(9): 1776-1782.
- Lam, T.S.; Meent, M. van de; Marijt, E.W.A.; Falkenburg, J.H.F. & Jedema, I. (2018), Immune surveillance by autoreactive CD4-positive helper T cells is a common phenomenon in patients with acute myeloid leukemia, European Journal of Haematology 101(5): 665-675.
- Balen, P. van; Bergen, C.A.M. van; Luxemburg-Heijs, S.A.P. van; Klerk, W. de; Egmond, E.H.M. van; Veld, S.A.J.; Halkes, C.J.M.; Zwaginga, J.J.; Griffioen, M.; Jedema, I. & Falkenburg, J.H.F. (2018), CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II, Frontiers in Immunology 9.
- Heiden, P.L.J. van der; Egmond, H.M. van; Veld, S.A.J.; Meent, M. van de; Eefting, M.; Wreede, L.C. de; Halkes, C.J.M.; Falkenburg, J.H.F.; Marijt, W.A.F. & Jedema, I. (2018), CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity, Transplant Immunology 49: 54-58.
- Luimstra, J.J.; Garstka, M.A.; Roex, M.C.J.; Redeker, A.; Janssen, G.M.C.; Veelen, P.A. van; Arens, R.; Falkenburg, J.H.F.; Neefjes, J. & Ovaa, H. (2018), A flexible MHC class I multimer loading system for large-scale detection of antigen-specific T cells, Journal of Experimental Medicine 215(5): 1493-1504.
- Meurer, T.; Arrieta-Bolanos, E.; Metzing, M.; Langer, M.M.; Balen, P. van; Falkenburg, J.H.F.; Beelen, D.W.; Horn, P.A.; Fleischhauer, K. & Crivello, P. (2018), Dissecting Genetic Control of HLA-DPB1 Expression and Its Relation to Structural Mismatch Models in Hematopoietic Stem Cell Transplantation, Frontiers in Immunology 9.
- Meurer Thuja, Bolanos Esteban Arrieta, Metzing Maximilian, Langer Mona, van Balen Peter, Falkenburg Frederick, Beelen Dietrich W., Horn Peter A., Fleischhauer Katharina & Crivello Pietro (2018), DISSECTING GENETIC CONTROL OF HLA-DPB1 EXPRESSION AND ITS RELATION TO STRUCTURAL MISMATCH MODELS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION, Hla 91(5): 339-339.
- Mousset, C.M.; Hobo, W.; Ji, Y.; Fredrix, H.; Giorgi, V. de; Allison, R.D.; Kester, M.G.D.; Falkenburg, J.H.F.; Schaap, N.P.M.; Jansen, J.H.; Gattinoni, L.; Dolstra, H. & Waart, A.B. van der (2018), Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8(+) T cells for adoptive immunotherapy, OncoImmunology 7(10).
- Loeff, F.C.; Falkenburg, J.H.F.; Hageman, L.; Huisman, W.; Veld, S.A.J.; Egmond, H.M.E. van; Meent, M. van de; Borne, P.A. von dem; Veelken, H.; Halkes, C.J.M. & Jedema, I. (2018), High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor(-)/CD52(-) T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell-Depleted Allogeneic Stem Cell Transplantation, Journal of Immunology 200(6): 2199-2208.
- Kremer, A.N.; Zonneveld, M.I.; Kremer, A.E.; Meijden, E.D. van der; Falkenburg, J.H.F.; Wauben, M.H.M.; Nolte-'t Hoen, E.N.M. & Griffioen, M. (2018), Natural T-cell ligands that are created by genetic variants can be transferred between cells by extracellular vesicles, European Journal of Immunology 48(10): 1621-1631.
- Luk, S.J.; Steen, D.M. van der; Hagedoorn, R.S.; Jordanova, E.S.; Schilham, M.W.; Bovee, J.V.M.G.; Cleven, A.H.G.; Falkenburg, J.H.F.; Szuhai, K. & Heemskerk, M.H.M. (2018), PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy, OncoImmunology 7(12).
- Bijen, H.M.; Steen, D.M. van der; Hagedoorn, R.S.; Wouters, A.K.; Wooldridge, L.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2018), Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs, Molecular Therapy 26(5): 1206-1214.
- Bijen, H.M.; Hassan, C.; Kester, M.G.D.; Janssen, G.M.C.; Hombrink, P.; Ru, A.H. de; Drijfhout, J.W.; Meiring, H.D.; Jong, A.P. de; Falkenburg, J.H.F.; Jimenez, C.R.; Heemskerk, M.H.M. & Veelen, P.A. van (2018), Specific TCell Responses against Minor Histocompatibility Antigens Cannot Generally Be Explained by Absence of Their Allelic Counterparts on the Cell Surface, Proteomics 18(12).
- Witte, M. de; Rhenen, A. van; Sluis, G. van; Admiraal, R.; Wagen, L. van der; Petersen, E.J.; Raymakers, R.; Minnema, M.C.; Janssen, A.; Westinga, K.; Halkes, C.J.M.; Falkenburg, J.H.F.; Boelens, J.J. & Kuball, J. (2018), First Results of a Prospective I/II Clinical Trial in Adult Patients Using TCR Alpha/Beta Depleted Stem Cell Transplantation from Matched Related and Unrelated Donors, Blood 132.
- Tjon, J.; Wreede, L. de; Falkenburg, F.; Groot, M. de; Koene, H.; Langemeijer, S.; Meijer, E.; Raaijmakers, M.; Raymakers, R.; Snijders, T.; Zeerleder, S. & Halkes, S. (2017), TREATMENT WITH HORSE-DERIVED ANTI-THYMOCYTE GLOBULIN LEADS TO ENDURING HEMATOLOGICAL RESPONSES AND A 1.5-YEAR SURVIVAL PROBABILITY OF 87% IN ADULT ACQUIRED APLASTIC ANEMIA PATIENTS IN THE NETHERLANDS, Haematologica 102: 223-224.
- Balen, P. van; Klerk, W. de; Meent, M. van de; Halkes, C.J.; Jedema, I. & Falkenburg, J. (2017), CD4 T CELLS RECOGNIZING MISMATCHED HLA-DP AFTER ALLOGENEIC STEM CELL TRANSPLANTATION SHOW TISSUE SPECIFIC REACTIVITIES, Haematologica 102: 162-163.
- Thordardottir, S.; Schaap, N.; Louer, E.; Kester, M.G.D.; Falkenburg, J.H.F.; Jansen, J.; Radstake, T.R.D.; Hobo, W. & Dolstra, H. (2017), Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivo, OncoImmunology 6(3).
- Jolink, H.; Boer, R. de; Hombrink, P.; Jonkers, R.E.; Dissel, J.T. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2017), Pulmonary immune responses against Aspergillus fumigatus are characterized by high frequencies of IL-17 producing T-cells, Journal of Infection 74(1): 81-88.
- Loeff, F.C.; Egmond, H.M.E. van; Nijmeijer, B.A.; Falkenburg, J.H.F.; Halkes, C.J. & Jedema, I. (2017), Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors, Leukemia & Lymphoma 58(9): 2185-2195.
- Balen, P. van; Luxemburg-Heijs, S.A.P. van; Meent, M. van de; Bergen, C.A.M. van; Halkes, C.J.M.; Jedema, I. & Falkenburg, J.H.F. (2017), Mismatched HLA-DRB3 Can Induce a Potent Immune Response After HLA 10/10 Matched Stem Cell Transplantation, Transplantation 101(12): 2850-2854.
- Hem, J.G.K. van der; Wreede, L.C. de; Brand, A.; Veelken, H.; Falkenburg, J.H.F. & Halkes, C.J.M. (2017), Long-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin, Haematologica 102(10): E382-E383.
- Bergen, C.A.M. van; Luxemburg-Heijs, S.A.P. van; Wreede, L.C. de; Eefting, M.; Borne, P.A. von dem; Balen, P. van; Heemskerk, M.H.M.; Mulder, A.; Claas, F.H.J.; Navarrete, M.A.; Honders, W.M.; Rutten, C.E.; Veelken, H.; Jedema, I.; Halkes, C.J.M.; Griffioen, M. & Falkenburg, J.H.F. (2017), Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response, Journal of Clinical Investigation 127(2): 517-529.
- Jahn, L.; Hombrink, P.; Hagedoorn, R.S.; Kester, M.G.D.; Steen, D.M. van der; Rodriguez, T.; Pentcheva-Hoang, T.; Ru, A.H.; Schoonakker, M.P.; Meeuwsen, M.H.; Griffioen, M.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2017), TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1, Blood 129(10): 1284-1295.
- Metzing, M.; Crivello, P.; Bolanos, E.A.; Meurer, T.; Bergen, K. van; Griffioen, M.; Horn, P.A.; Falkenburg, F. & Fleischhauer, K. (2017), HLA-DM MEDIATES PERMISSIVENESS OF T-CELL ALLOREACTIVITY TO HLA-DPB1, Hla 89(6): 338-338.
- Meurer, T.; Bolanos, E.A.; Metzing, M.; Crivello, P.; Bergen, K. van; Balen, P. van; Horn, P.A.; Falkenburg, F. & Fleischhauer, K. (2017), DISSECTING THE RELATIVE ROLE OF STRUCTURAL AND EXPRESSION POLYMORPHISM FOR T-CELL ALLORECOGNITION OF HLA-DPB1, Hla 89(6): 338-339.
- Franssen, L.E.; Roeven, M.W.H.; Hobo, W.; Doorn, R.; Oostvogels, R.; Falkenburg, J.H.F.; Donk, N.W. van de; Kester, M.G.D.; Fredrix, H.; Westinga, K.; Slaper-Cortenbach, I.; Spierings, E.; Kersten, M.J.; Dolstra, H.; Mutis, T.; Schaap, N. & Lokhorst, H.M. (2017), A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma, Bone Marrow Transplantation 52(10): 1378-1383.
- Bolanos, E.A.; Crivello, P.; Metzing, M.; Meurer, T.; Rytlewski, J.; Vignali, M.; Yusko, E.; Bergen, K. van; Balen, P. van; Falkenburg, F. & Fleischhauer, K. (2017), ALLOREACTIVITY AGAINST HLA-DPB1 MOLECULES ARISES FROM DIVERSE T-CELL RECEPTOR REPERTOIRES IN THE PERMISSIVE AND NON-PERMISSIVE CONTEXT, Hla 89(6): 357-357.
- Falkenburg, J.H.F. & Jedema, I. (2017), Graft versus tumor effects and why people relapse, Hematology: 693-698.
- Eefting, M.; Wreede, L.C. de; Borne, P.A. von dem; Halkes, C.J.M.; Kersting, S.; Marijt, E.W.A.; Putter, H.; Veelken, H.; Schetelig, J. & Falkenburg, J.H.F. (2017), Donor T-cell responses and disease progression patterns of multiple myeloma, Bone Marrow Transplantation 52(12): 1609-1615.
- Cruijsen, M.; Hobo, W.; Velden, W.J.F.M. van der; Bremmers, M.E.J.; Woestenenk, R.; Bar, B.; Falkenburg, J.H.F.; Kester, M.; Schaap, N.P.M.; Jansen, J.; Blijlevens, N.N.M.; Dolstra, H. & Huls, G. (2016), Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses, Biology of Blood and Marrow Transplantation 22(6): 1000-1008.
- Caruana, I.; Orlando, D.; Angelis, B. de; Boffa, I.; Guercio, M.; Carai, A.; Massimi, L.; Ferretti, E.; Miele, E.; Po, A.; Moseley, A.; Hagedoorn, R.S.; Boer, R. de; Falkenburg, J.H.F.; Heemskerk, M.H.M.; Locatelli, F.; Mastronuzzi, A. & Quintarelli, C. (2016), ADOPTIVE CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA BASED ON T CELLS REDIRECTED TOWARD TUMOR CELLS BY PRAME SPECIFIC alpha beta TCR GENE MODIFICATION, Neuro-Oncology 18: 111-111.
- Arrieta-Bolanos, E.; Crivello, P.; Bergen, K. van; Metzing, M.; Balen, P. van; Horn, P.A.; Falkenburg, F. & Fleischhauer, K. (2016), ALLOREACTIVITY TO HLA-DP IS MODULATED BY SELF T-CELL EPITOPES IN THE RESPONDER, Hla 87(4): 204-204.
- Griffioen, M.; Bergen, C.A.M. van & Falkenburg, J.H.F. (2016), Autosomal Minor Histocompatibility Antigens: How Genetic variants Create Diversity in immune Targets, Frontiers in Immunology 7.
- Loeff, F.; Falkenburg, J.F.; Hageman, L.; Veld, S.; Meent, M.V. de; Halkes, S. & Jedema, I. (2016), A POLYCLONAL POPULATION OF PIGA MUTANT CD52 AND GPI-ANCHOR NEGATIVE T-CELLS CAN GIVE EARLY IMMUNE PROTECTION AFTER ALEMTUZUMAB-BASED T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION, Haematologica 101: 286-286.
- Lamers, C.H.J.; Wijers, R.; Bergen, C.A.M. van; Somers, J.A.E.; Braakman, E.; Gratama, J.W.; Debets, R.; Falkenburg, J.H.F. & Cornelissen, J.J. (2016), CD4(+) T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation, Blood 128(17): 2165-2174.
- Eefting, M.; Wreede, L.C. de; Halkes, C.J.M.; Borne, P.A. von dem; Kersting, S.; Marijt, E.W.A.; Veelken, H.; Putter, H.; Schetelig, J. & Falkenburg, J.H.F. (2016), Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion, Haematologica 101(4): 506-514.
- Pont, M.J.; Honders, M.W.; Kremer, A.N.; Kooten, C. van; Out, C.; Hiemstra, P.S.; Boer, H.C. de; Jager, M.J.; Schmelzer, E.; Vries, R.G.; Hinai, A.S. al; Kroes, W.G.; Monajemi, R.; Goeman, J.J.; Bohringer, S.; Marijt, W.A.F.; Falkenburg, J.H.F. & Griffioen, M. (2016), Microarray gene expression analysis to evaluate cell type specific expression of targets relevant for immunotherapy of hematological malignancies., PLoS Medicine 11.
- Lee, D.I. van der; Pont, M.J.; Falkenburg, J.H.F. & Griffioen, M. (2016), The Value of Online Algorithms to Predict T-Cell Ligands Created by Genetic Variants, PLoS ONE 11(9).
- Jahn, L.; Steen, D.M. van der; Hagedoorn, R.S.; Hombrink, P.; Kester, M.G.D.; Schoonakker, M.P.; Ridder, D. de; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2016), Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies, Oncotarget 7(47): 77021-77037.
- Balen, P. van; Meent, M. van de; Luxemburg-Heijs, S.A. van; Halkes, C.J.; Jedema, I. & Falkenburg, J. (2016), CD4 T-cells directed against mismatched HLA-DP isolated following donor CD4 T-cell infusion after allogeneic stem cell transplantation show differential tissue recognition, Bone Marrow Transplantation 51: S362-S363.
- Wojcik, B.; Lang, F.B.A.; Oellerich, T.; Falkenburg, J.H.; Bruggemann, M.; Schroeder, T.; Serve, H.; Ottmann, O. & Rieger, M. (2016), PLASTIC SURFACE MARKER EXPRESSION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA EXPLAINS AMBIGUITY OF LEUKEMIA-INITIATING STEM CELL POPULATIONS, Experimental Hematology 44(9): S108-S108.
- Pont, M.J.; Honders, M.W.; Kremer, A.N.; Kooten, C. van; Out, C.; Hiemstra, P.S.; Boer, H.C. de; Jager, M.J.; Schmelzer, E.; Vries, R.G.; Hinai, A.S. al; Kroes, W.G.; Monajemi, R.; Goeman, J.J.; Bohringer, S.; Marijt, W.A.F.; Falkenburg, J.H.F. & Griffioen, M. (2016), Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies, PLoS ONE 11(5).
- Loeff, F.; Rijs, K.; Egmond, E. van; Zoutman, W.; Vermeer, M.; Falkenburg, J.F.; Halkes, S. & Jedema, I. (2016), LOSS OF PIGH EXPRESSION FREQUENTLY RESULTS IN A GPI-NEGATIVE SUBCLONE LACKING CD52 MEMBRANE EXPRESSION, CONFERRING ALEMTUZUMAB RESISTANCE TO B CELL ACUTE LYMPHOBLASTIC LEUKEMIA, Haematologica 101: 29-30.
- Laghmouchi, A.; Hoogstraten, C.; Balen, P. van; Meent, M. van de; Falkenburg, J.F. & Jedema, I. (2016), In-vitro generation of allo-HLA-DP-restricted donor T-cells with hematopoiesis- and cell-lineage-specificity for therapeutic application, Bone Marrow Transplantation 51: S110-S110.
- Pont, M.J.; Lee, D.I. van der; Meijden, E. van der; Bergen, C.A.M. van; Kester, M.G.D.; Honders, M.W.; Vermaat, M.; Eefting, M.; Marijt, E.W.A.; Kielbasa, S.M.; Hoen, P.A.C. 't; Falkenburg, J.H.F. & Griffioen, M. (2016), Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2, Clinical Cancer Research 22(16): 4185-4196.
- Waart, A.B. van der; Mousset, C.M.; Fredrix, H.; Weem, N.M. van de; Maas, F.; Kester, M.G.; Falkenburg, J.F.; Schaap, N.; Jansen, J.H.; Voort, R. van der; Gattinoni, L.; Hobo, W. & Dolstra, H. (2016), Inhibition of Akt-signaling promotes the generation of superior tumor-reactive T cells for immunotherapy post allogeneic stem cell transplantation, Bone Marrow Transplantation 51: S111-S112.
- Cornelissen, J.; Wijers, R.; Bergen, C. van; Somers, J.; Braakman, E.; Gratama, J.; Debets, R.; Falkenburg, F. & Lamers, C. (2016), Graft predominance and graft versus leukemia early after double Umbilical Cord Blood Transplantation (dUCBT): a novel role for CD4+T-cell effector alloreactivity towards mismatched HLA class alleles, Bone Marrow Transplantation 51: S65-S66.
- Jahn, L.; Hagedoorn, R.S.; Steen, D.M. van der; Hombrink, P.; Kester, M.G.D.; Schoonakker, M.P.; Ridder, D. de; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2016), A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer, Oncotarget 7(44): 71536-71547.
- Borne, P.A.V.; Wreede, L.C. de; Halkes, C.J.M.; Marijt, W.A.F.; Falkenburg, J.H.F. & Veelken, H. (2016), Effectivity of a strategy in elderly AML patients to reach allogeneic stem cell transplantation using intensive chemotherapy: Long-term survival is dependent on complete remission after first induction therapy, Leukemia Research 46: 45-50.
- Zaliova, M.; Moorman, A.V.; Cazzaniga, G.; Stanulla, M.; Harvey, R.C.; Roberts, K.G.; Heatley, S.L.; Loh, M.L.; Konopleva, M.; Chen, I.M.; Zimmermannova, O.; Schwab, C.; Smith, O.; Mozziconacci, M.J.; Chabannon, C.; Kim, M.; Falkenburg, J.H.F.; Norton, A.; Marshall, K.; Haas, O.A.; Starkova, J.; Stuchly, J.; Hunger, S.P.; White, D.; Mullighan, C.G.; Willman, C.L.; Stary, J.; Trka, J. & Zuna, J. (2016), Characterization of leukemias with ETV6-ABL1 fusion, Haematologica 101(9): 1082-1093.
- Szabo, A.; Dinmohamed, A.; Holt, B. van der; Versluis, J.; Groot, M. de; Zeerleder, S.; Schouten, H.; Schaap, M.; Meijer, E.; Petersen, E.; Falkenburg, F.; Rijneveld, A. & Cornelissen, J. (2016), CONSOLIDATION BY ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CR1 AGED 40-69 YEARS: A COMPARISON OF MYELOABLATIVE AND REDUCED INTENSITY CONDITIONING, Haematologica 101: 108-109.
- Roex, M.; Luna, J.M.; Hageman, L.; Egmond, E. van; Veld, S.; Liempt, E. van; Hoogstraten, C.; Germeroth, L.; Balen, P. van; Halkes, S.; Falkenburg, J.F. & Jedema, I. (2016), COMBINED ISOLATION OF MULTI ANTIGEN SPECIFIC T CELL PRODUCTS CONTAINING NAIVE AND/OR MEMORY VIRUS-SPECIFIC T CELLS AND T CELLS SPECIFIC FOR TUMOR ASSOCIATED AND MINOR HISTOCOMPATIBILITY ANTIGENS, Haematologica 101: 464-464.
- Roex, M.; Luna, J.M.; Hageman, L.; Liempt, E. van; Egmond, E. van; Veld, S.; Hoogstraten, C.; Germeroth, L.; Balen, P. van; Halkes, C.; Falkenburg, F. & Jedema, I. (2016), Combined isolation of virus specific T cells from seronegative donors, TAA and MiHA specific T cells for the prevention of viral infections and tumor relapses early after alloSCT, Bone Marrow Transplantation 51: S316-S317.
- Bergen, C.A.M. van; Steen, D.M. van der; Kester, M.G.D.; Koning, M.T.; Veelen, P.A. van; Griffioen, M.; Falkenburg, J.H.F.; Heemskerk, M.H.M.; Veelken, H. & Navarrete, M.A. (2016), Endogenous Immunoglobulin-Derived Neoepitopes Are Processed and Form a Sizeable Fraction of the HLA Class I Ligandome of Human Lymphoma Cells, Blood 128(22).
- Hem, J.V.D.; Wreede, L.D.; Brand, A.; Veelken, H.; Falkenburg, F. & Halkes, C. (2015), Increased risk of development of malignancies in adult patients treated with antithymocyte globulin as first line treatment for aplastic anaemia during a follow-up period of thirty years., Bone Marrow Transplantation 50: S86-S86.
- Lam, T.S.; Meent, M. van de; Falkenburg, J.H.F. & Jedema, I. (2015), Monocyte-derived dendritic cells can induce autoreactive CD4(+) T cells showing myeloid lineage directed reactivity in healthy individuals, European Journal of Immunology 45(4): 1030-1042.
- Falkenburg, J.H.F. & Jedema, I. (2015), Allo-reactive T cells for the treatment of hematological malignancies, Molecular Oncology 9(10): 1894-1903.
- Cornelissen, J.J.; Wijers, R.; Bergen, C.A.M. van; Somers, J.; Braakman, E.; Gratama, J.W.; Debets, R.; Falkenburg, J.H.F. & Lamers, C. (2015), Early CD4+T-Cell Effector Alloreactivity Towards Multiple Mismatched HLA Class II Alleles Is Associated with Graft Predominance after Double Umbilical Cord Blood Transplantation (dUCBT), Blood 126(23).
- Jahn, L.; Hagedoorn, R.S.; Hombrink, P.; Kester, M.G.D.; Steen, D.M. van der; Hassan, C.; Schoonakker, M.P.; Pijl, E. van der; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2015), Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies, Blood 126(23).
- Hassan, C.; Chabrol, E.; Jahn, L.; Kester, M.G.D.; Ru, A.H. de; Drijfhout, J.W.; Rossjohn, J.; Falkenburg, J.H.F.; Heemskerk, M.H.M.; Gras, S. & Veelen, P.A. van (2015), Naturally Processed Non-canonical HLA-A*02:01 Presented Peptides, Journal of Biological Chemistry 290(5): 2593-2603.
- Sarah E. Alford, Anisha Kothari, Floris C. Loeff, Joshua M. Eichhorn, Nandini Sakurikar, Henriette M. Goselink, Robert L. Saylors, Inge Jedema, J.H. Frederik Falkenburg & and Timothy C. Chambers (2015), BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
- Hombrink, P.; Hassan, C.; Kester, M.G.D.; Jahn, L.; Pont, M.J.; Ru, A.H. de; Bergen, C.A.M. van; Griffioen, M.; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2015), Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach, Clinical Cancer Research 21(9): 2177-2186.
- Jahn, L.; Hombrink, P.; Hassan, C.; Kester, M.G.D.; Steen, D.M. van der; Hagedoorn, R.S.; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2015), Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b, Blood 125(6): 949-958.
- Loeff, F.C.; Falkenburg, J.H.F.; Hageman, L.; Veld, S.A.J.; Meent, M. van de; Halkes, C.J.M. & Jedema, I. (2015), A Polyclonal Population of Piga Mutant CD52 and GPI Anchor Negative T Cells Can Give Early Immune Protection after Alemtuzumab-Based T Cell Depleted Allogeneic Stem Cell Transplantation, Blood 126(23).
- Alford, S.E.; Kotharil, A.; Loeff, F.C.; Eichhorn, J.M.; Sakurikar, N.; Goselink, H.M.; Saylors, R.L.; Jedema, I.; Falkenburg, J.H.F. & Chambers, T.C. (2015), BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells, Cancer Research 75(7): 1366-1375.
- Roex, M.; Liempt, E. van; Hageman, L.; Germeroth, L.; Halkes, C.; Falkenburg, F. & Jedema, I. (2015), A Multi-Antigen Specific T Cell Product for the Prevention of Viral Infections and Tumor Relapses Early after Allogeneic Stem Cell Transplantation, Bone Marrow Transplantation 50: S313-S314.
- Eefting, M.; Wreede, L. de; Borne, P.V.; Halkes, C.; Kersting, S.; Marijt, E.; Putter, H.; Veelken, H.; Schetelig, J. & Falkenburg, F. (2015), Donor T-cell responses modulate disease progression patterns of multiple myeloma after T-cell depleted allogeneic stem cell transplantation, Bone Marrow Transplantation 50: S15-S16.
- Passweg, J.R.; Baldomero, H.; Bader, P.; Bonini, C.; Cesaro, S.; Dreger, P.; Duarte, R.F.; Dufour, C.; Falkenburg, J.H.F.; Farge-Bancel, D.; Gennery, A.; Kroger, N.; Lanza, F.; Nagler, A.; Sureda, A.; Mohty, M. & European Soc Blood Marrow (2015), Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants, Bone Marrow Transplantation 50(4): 476-482.
- Sureda, A.; Bader, P.; Cesaro, S.; Dreger, P.; Duarte, R.F.; Dufour, C.; Falkenburg, J.H.F.; Farge-BanceI, D.; Gennery, A.; Kroger, N.; Lanza, F.; Marsh, J.C.; Nagler, A.; Peters, C.; Velardi, A.; Mohty, M.; Madrigal, A. & European Soc Blood Marrow (2015), Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015, Bone Marrow Transplantation 50(8): 1037-1056.
- Pont, M.J.; Hobo, W.; Honders, M.W.; Luxemburg-Heijs, S.A.P. van; Kester, M.G.D.; Oeveren-Rietdijk, A.M. van; Schaap, N.; Boer, H.C. de; Bergen, C.A.M. van; Dolstra, H.; Falkenburg, J.H.F. & Griffioen, M. (2015), LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application, Haematologica 100(10): E419-E422.
- Jolink, H.; Boer, R. de; Willems, L.N.A.; Dissel, J.T. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2015), T helper 2 response in allergic bronchopulmonary aspergillosis is not driven by specific Aspergillus antigens, Allergy 70(10): 1336-1339.
- Loenen, M.M. van; Boer, R. de; Liempt, E. van; Meij, P.; Jedema, I.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2014), A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells, Haematologica 99(4): 759-768.
- Zimmermannova, O.; Zuna, J.; Machova, K.; Lizcova, L.; Zemanova, Z.; Falkenburg, J.; Harvey, R.; Chen, I.M.; Willman, C.L.; Trka, J. & Zaliova, M. (2014), MODELING RESISTANCE TO TYROSINE KINASE INHIBITORS IN TEL/ABL plus ACUTE LYMPHOBLASTIC LEUKEMIA, Haematologica 99: 271-272.
- Eefting, M.; Borne, P.A. von dem; Wreede, L.C. de; Halkes, C.J.M.; Kersting, S.; Marijt, E.W.A.; Veelken, H. & Falkenburg, J.H.F. (2014), Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation, Haematologica 99(4): 751-758.
- Waart, A.B. van der; Weem, N.M.P. van de; Maas, F.; Kramer, C.S.M.; Kester, M.G.D.; Falkenburg, J.H.F.; Schaap, N.; Jansen, J.H.; Voort, R. van der; Gattinoni, L.; Hobo, W. & Dolstra, H. (2014), Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy, Blood 124(23): 3490-3500.
- Jolink, H.; Hagedoorn, R.S.; Lagendijk, E.L.; Drijfhout, J.W.; Dissel, J.T. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2014), Induction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis.
- Kretschmann, S.; Bruns, H.; Falkenburg, J.H.F.; Mackensen, A.; Griffioen, M. & Kremer, A. (2014), Indirect presentation of Y-chromosome antigen DBY requires protein structures outside of the T-cell epitope, Oncology Research and Treatment 37: 210-210.
- Kremer, A.N.; Meijden, E.D. van der; Honders, M.W.; Pont, M.J.; Goeman, J.J.; Falkenburg, J.H.F. & Griffioen, M. (2014), Human Leukocyte Antigen-DO Regulates Surface Presentation of Human Leukocyte Antigen Class-II Restricted Antigens on B Cell Malignancies, Biology of Blood and Marrow Transplantation 20(5): 742-747.
- Jahn, L.; Hombrink, P.; Hassan, C.; Kester, M.G.D.; Hagedoorn, R.S.; Schoonakker, M.P.; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2014), High-affinity CD20-specific TCRs suitable for adoptive immunotherapy in the treatment of CD20low B cell malignancies, Human Gene Therapy 25(11): A92-A92.
- Bergen, C.A.M. van; Verdegaal, E.M.E.; Honders, M.W.; Hoogstraten, C.; Steijn-van Tol, A.Q.M.J.; Quartel, L. de; Jong, J. de; Meyering, M.; Falkenburg, J.H.F.; Griffioen, M. & Osanto, S. (2014), Durable Remission of Renal Cell Carcinoma in Conjuncture with Graft versus Host Disease following Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion: Rule or Exception?, PLoS ONE 9(1).
- Passweg, J.R.; Baldomero, H.; Peters, C.; Gaspar, H.B.; Cesaro, S.; Dreger, P.; Duarte, R.F.; Falkenburg, J.H.F.; Farge-Bancel, D.; Gennery, A.; Halter, J.; Kroger, N.; Lanza, F.; Marsh, J.; Mohty, M.; Sureda, A.; Velardi, A.; Madrigal, A. & European Soc Blood Marrow Transpla (2014), Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation, Bone Marrow Transplantation 49(6): 744-750.
- Pont, M.J.; Bergen, C.A.M. van; Honders, M.W.; Luxemburg-Heijs, S.A.P. van; Kester, M.G.D.; Falkenburg, J.H.F. & Griffioen, M. (2014), Donor T-cells for hematopoietic-restricted minor histocompatibility antigens are induced in patients with combined Graft-versus-Leukemia and Graft-versus-Host disease, Human Gene Therapy 25(11): A40-A40.
- Kremer, A.N.; Griendt, J.C. van der; Meijden, E.D. van der; Honders, M.W.; Ayoglu, B.; Schwenk, J.M.; Nilsson, P.; Falkenburg, J.H.F. & Griffioen, M. (2014), Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation, Haematologica 99(2): 365-369.
- Zouwen, B. van der; Kruisselbrink, A.B.; Falkenburg, J.H.F. & Jedema, I. (2014), Collateral Damage of Nonhematopoietic Tissue by Hematopoiesis-Specific T Cells Results in Graft-versus-Host Disease During an Ongoing Profound Graft-versus-Leukemia Reaction, Biology of Blood and Marrow Transplantation 20(6): 760-769.
- Jahn, L.; Hombrink, P.; Kester, M.G.D.; Schoonakker, M.P.; Falkenburg, J.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2014), HIGH-AFFINITY CD20-SPECIFIC TCRS SUITABLE FOR ADOPTIVE IMMUNOTHERAPY CAN BE READILY ISOLATED FROM THE ALLO-REPERTOIRE USING REVERSE IMMUNOLOGY, Bone Marrow Transplantation 49: S17-S17.
- Jahn, L.; Hombrink, P.; Hassan, C.; Kester, M.G.D.; Hagedoorn, R.S.; Steen, D.M. van der; Schoonakker, M.P.; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2014), High-Affinity CD20-Specific T-Cell Receptors Suitable for Adoptive Immunotherapy in the Treatment of CD20(low) B-Cell Malignancies, Blood 124(21).
- Jahn, L.; Hombrink, P.; Kester, M.G.D.; Steen, D.M. van der; Hagedoorn, R.S.; Hassan, C.; Schoonakker, M.P.; Pijl, E. van der; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2014), T Cell Receptors Specific for the Intracellular Transcription Factor Bob1 Allow Efficient Targeting of Human B Cell Leukemia and Multiple Myeloma, Blood 124(21).
- Hassan, C.; Kester, M.G.D.; Oudgenoeg, G.; Ru, A.H. de; Janssen, G.M.C.; Drijfhout, J.W.; Spaapen, R.M.; Jimenez, C.R.; Heemskerk, M.H.M.; Falkenburg, J.H.F. & Veelen, P.A. van (2014), Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes, Journal of Proteomics 109: 240-244.
- Eefting, M.; Halkes, C.J.M.; Wreede, L.C. de; Pelt, C.M. van; Kersting, S.; Marijt, E.W.A.; Borne, P.A. von dem; Willemze, R.; Veelken, H. & Falkenburg, J.H.F. (2014), Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL, Bone Marrow Transplantation 49(2): 287-291.
- Jolink, H.; Meijssen, I.C.; Hagedoorn, R.S.; Arentshorst, M.; Drijfhout, J.W.; Mulder, A.; Claas, F.H.J.; Dissel, J.T. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2013), Characterization of the T-Cell-Mediated Immune Response Against the Aspergillus fumigatus Proteins Crf1 and Catalase 1 in Healthy Individuals.
- Rutten, C.E.; Luxemburg-Heijs, S.A.P. van; Halkes, C.J.M.; Bergen, C.A.M. van; Marijt, E.W.A.; Oudshoorn, M.; Griffioen, M. & Falkenburg, J.H.F. (2013), Patient HLA-DP-Specific CD4(+) T Cells from HLA-DPB1-Mismatched Donor Lymphocyte Infusion Can Induce Graft-versus-Leukemia Reactivity in the Presence or Absence of Graft-versus-Host Disease, Biology of Blood and Marrow Transplantation 19(1): 40-48.
- Badura, S.; Tesanovic, T.; Pfeifer, H.; Wystub, S.; Nijmeijer, B.A.; Liebermann, M.; Falkenburg, J.H.F.; Ruthardt, M. & Ottmann, O.G. (2013), Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia, PLoS ONE 8(11).
- Falkenburg, J.H.F. (2013), MECHANISMS OF ANTI-TUMOR T CELL THERAPY FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION, Vox Sanguinis 105: 44-45.
- Hombrink, P.; Raz, Y.; Kester, M.G.D.; Boer, R. de; Weissbrich, B.; Borne, P.A. von dem; Busch, D.H.; Schumacher, T.N.M.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2013), Mixed functional characteristics correlating with TCR-ligand k(off)-rate of MHC-tetramer reactive T cells within the naive T-cell repertoire, European Journal of Immunology 43(11): 3038-3050.
- Thielen, N.; Holt, B. van der; Verhoef, G.E.G.; Ammerlaan, R.A.H.M.; Sonneveld, P.; Janssen, J.J.W.M.; Deenik, W.; Falkenburg, J.H.F.; Kersten, M.J.; Sinnige, H.A.M.; Schipperus, M.; Schattenberg, A.; Kooy, R.V.; Smit, W.M.; Chu, I.W.T.; Valk, P.J.M.; Ossenkoppele, G.J. & Cornelissen, J.J. (2013), High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group, Annals of Hematology 92(8): 1049-1056.
- Eefting, M.; Borne, P.V.; Wreede, L. de; Halkes, C.; Kersting, S.; Marijt, E.; Veelken, H. & Falkenburg, F. (2013), Induction of limited acute GvHD by donor lymphocyte infusion early after cytoreduction is essential for long-term survival of patients with relapsed acute myeloid leukaemia after allogeneic stem cell transplantation, Bone Marrow Transplantation 48: S250-S250.
- Loenen, M.M. van; Boer, R. de; Hagedoorn, R.S.; Jankipersadsing, V.; Amir, A.L.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2013), Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells, Gene Therapy 20(8): 861-867.
- Eefting, M.; Halkes, C.; Wreede, L. de; Pelt, M. van; Kersting, S.; Marijt, E.; Borne, P. von dem; Willemze, R.; Veelken, H. & Falkenburg, F. (2013), Myeloablative T-cell depleted allogeneic stem cell transplantation with early sequential prophylactic donor lymphocyte infusion for adult acute lymphoblastic leukaemia in first complete remission, Bone Marrow Transplantation 48: S395-S395.
- Stevanovic, S.; Nijmeijer, B.A.; Schie, M.L.J. van; Salvatori, D.C.F.; Maas, S.; Griffioen, M. & Falkenburg, J.H.F. (2013), Donor T Cells Administered Over HLA Class II Barriers Mediate Antitumor Immunity without Broad Off-Target Toxicity in a NOD/Scid Mouse Model of Acute Leukemia, Biology of Blood and Marrow Transplantation 19(6): 867-875.
- Jedema, I.; Hoogstraten, C.; Meent, M. van de; Lam, T.S. & Falkenburg, J.H.F. (2013), In vitro generation of therapeutic haematopoiesis-directed donor T-cell products allowing broad clinical application in patients with different haematological malignancies, Bone Marrow Transplantation 48: S78-S79.
- Passweg, J.R.; Baldomero, H.; Bregni, M.; Cesaro, S.; Dreger, P.; Duarte, R.F.; Falkenburg, J.H.F.; Kroger, N.; Farge-Bancel, D.; Gaspar, H.B.; Marsh, J.; Mohty, M.; Peters, C.; Sureda, A.; Velardi, A.; Elvira, C.R. de; Madrigal, A. & European Grp Blood Marrow Transpla (2013), Hematopoietic SCT in Europe: data and trends in 2011, Bone Marrow Transplantation 48(9): 1161-1167.
- Hombrink, P.; Hassan, C.; Kester, M.G.D.; Ru, A.H. de; Bergen, C.A.M. van; Nijveen, H.; Drijfhout, J.W.; Falkenburg, J.H.F.; Heemskerk, M.H.M. & Veelen, P.A. van (2013), Discovery of T Cell Epitopes Implementing HLA-Peptidomics into a Reverse Immunology Approach, Journal of Immunology 190(8): 3869-3877.
- Hoozemans, M.; Timmerman, W.; Boerrigter, G. & Falkenburg, J.H.F. (2013), Creating a platform for translational research in The Netherlands, European Journal of Cancer 49: S327-S327.
- Balen, P. van; Bergen, A.M. van; Jedema, I.; Luxemburg-Heijs, S.A.P. van; Harskamp, J.C.; Egmond, H.M. van; Veld, S.A.J.; Griffioen, M.; Marijt, W.A.F.; Halkes, C.J.M. & Falkenburg, J.H.F. (2013), Purified CD4 T-cell infusion can result in graft-versus-leukaemia without GVHD by recognition of broadly expressed minor histocompatibility antigens restricted by HLA class-II, Bone Marrow Transplantation 48: S12-S13.
- Stevanovic, S.; Schie, M.L.J. van; Griffioen, M. & Falkenburg, J.H. (2013), HLA-class II disparity is necessary for effective T cell mediated Graft-versus-Leukemia effects in NOD/scid mice engrafted with human acute lymphoblastic leukemia, Leukemia 27(4): 985-987.
- Zouwen, B. van der; Kruisselbrink, A.B.; Falkenburg, J.H. & Jedema, I. (2013), HEMATOPOIESIS-SPECIFIC T-CELLS MAY CONTRIBUTE TO GVHD REACTIVITY BY INDUCTION OF COLLATERAL DAMAGE TO NON-HEMATOPOIETIC TISSUES DURING AN ONGOING PROFOUND GVL REACTION, Cytotherapy 15(4): S9-S10.
- Lam, T.S.; Meent, M. van de; Falkenburg, J.H.F. & Jedema, I. (2013), Generation of therapeutic minor histocompatibility antigen-specific donor T-cells using an 'in-vitro vaccination strategy', Bone Marrow Transplantation 48: S78-S78.
- Stevanovic, S.; Bergen, C.A.M. van; Luxemburg-Heijs, S.A.P. van; Zouwen, B. van der; Jordanova, E.S.; Kruisselbrink, A.B.; Meent, M.V. de; Harskamp, J.C.; Claas, F.H.J.; Marijt, E.W.A.; Zwaginga, J.J.; Halkes, C.J.M.; Jedema, I.; Griffioen, M. & Falkenburg, J.H.F. (2013), HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+donor lymphocyte infusion, Blood 122(11): 1963-1973.
- Verkaik, N.J.; Hoek, R.A.S.; Bergeijk, H. van; Hal, P.T.W. van; Schipper, M.E.I.; Pas, S.D.; Beersma, M.F.C.; Boucher, C.A.B.; Jedema, I.; Falkenburg, F.; Hoogsteden, H.C.; Blink, B. van den & Murk, J.L. (2013), Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature, Transplant Infectious Disease 15(6): E243-E249.
- Hassan, C.; Kester, M.G.D.; Ru, A.H. de; Hombrink, P.; Drijfhout, J.W.; Nijveen, H.; Leunissen, J.A.M.; Heemskerk, M.H.M.; Falkenburg, J.H.F. & Veelen, P.A. van (2013), The Human Leukocyte Antigen-presented Ligandome of B Lymphocytes, Molecular and Cellular Proteomics 12(7): 1829-1843.
- Jedema, I.; Hoogstraten, C.; Liempt, P.A. van; Meent, M. van de & Falkenburg, J.H. (2013), PRODUCTION OF LEUKEMIA-REACTIVE T-CELLS VIA A GOOD MANUFACTURING PRACTICE PROCEDURE FOR TREATMENT OF PATIENTS WITH ACUTE OR CHRONIC B-CELL MALIGNANCIES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION, Cytotherapy 15(4): S10-S10.
- Loenen, M.M. van; Hagedoorn, R.S.; Boer, R. de; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2013), Extracellular Domains of CD8 alpha and CD8ss Subunits Are Sufficient for HLA Class I Restricted Helper Functions of TCR-Engineered CD4(+) T Cells, PLoS ONE 8(5).
- Somers, J.A.E.; Brand, A.; Hensbergen, Y. van; Mulder, A.; Oudshoorn, M.; Sintnicolaas, K.; Gratama, J.W.; Falkenburg, J.H.F.; Braakman, E. & Cornelissen, J.J. (2013), Double Umbilical Cord Blood Transplantation: A Study of Early Engraftment Kinetics in Leukocyte Subsets using HLA-Specific Monoclonal Antibodies., Biology of Blood and Marrow Transplantation 19(2): 266-73.
- Hobo, W.; Broen, K.; Velden, W.J.F.M. van der; Greupink-Draaisma, A.; Adisty, N.; Wouters, Y.; Kester, M.; Fredrix, H.; Jansen, J.H.; Reijden, B. van der; Falkenburg, J.H.F.; Witte, T. de; Preijers, F.; Schattenbere, T.; Feuth, T.; Blijlevens, N.M.; Schaap, N. & Dolstra, H. (2013), Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation., Biology of Blood and Marrow Transplantation 19(2): 274-82.
- Halkes, C.; Falkenburg, J.; Egmond, E. van; Wolbers, J.O.; Starrenburg, I.; Borne, P. von dem; Marijt, W.A.F.; Veelken, J.H. & Jedema, I. (2012), Rabbit-derived ATG but not horse-derived ATG in the conditioning induces a post transplant in vivo imbalance between B and T cell recovery resulting in high risk of EBV-associated PTLD, Bone Marrow Transplantation 47: S143-S143.
- Borne, P.A.V.; Halkes, C.J.M.; Marijt, E.W.A.; Kersting, S.; Falkenburg, J.H.F. & Veelken, J.H. (2012), Effectiveness of a Strategy to Proceed to Allogeneic Stem Cell Transplantation in All Elderly AML Patients Treated with Intensive Chemotherapy: Only Patients in Complete Remission After First Induction Show Long Term Survival., Blood 120(21).
- Meij, P.; Jedema, I.; Zandvliet, M.L.; Heiden, P.L.J. van der; Meent, M. van de; Egmond, H.M.E. van; Liempt, E. van; Hoogstraten, C.; Kruithof, S.; Veld, S.; Marijt, E.W.A.; Borne, P.A. von dem; Lankester, A.C.; Halkes, C.J.M. & Falkenburg, J.H.F. (2012), Effective Treatment of Refractory CMV Reactivation After Allogeneic Stem Cell Transplantation With In Vitro-generated CMV pp65-specific CD8(+) T-cell Lines, Journal of Immunotherapy 35(8): 621-628.
- Kremer, A.N.; Meijden, E.D. van der; Honders, M.W.; Goeman, J.J.; Wiertz, E.J.H.J.; Falkenburg, J.H.F. & Griffioen, M. (2012), Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO, Blood 120(16): 3246-3255.
- Griendt, J.C. van der; Meijden, E.D. van der; Ayoglu, B.; Schwenk, J.; Nilsson, P.; Falkenburg, J.H.F. & Griffioen, M. (2012), Development of antibody responses against H-Y antigens and their X-variants after allogeneic haematopoietic stem cell transplantation and donor lymphocyte infusion, Bone Marrow Transplantation 47: S314-S315.
- Zandvliet, M.L.; Kester, M.G.D.; Liempt, E. van; Ru, A.H. de; Veelen, P.A. van; Griffioen, M.; Guchelaar, H.J.; Falkenburg, J.H.F. & Meij, P. (2012), Efficiency and Mechanism of Antigen-specific CD8(+) T-cell Activation Using Synthetic Long Peptides, Journal of Immunotherapy 35(2): 142-153.
- Stevanovic, S.; Griffioen, M.; Nijmeijer, B.A.; Schie, M.L.J. van; Stumpf, A.N.; Rutten, C.E.; Willemze, R. & Falkenburg, J.H.F. (2012), Human allo-reactive CD4+T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia, Leukemia 26(2): 312-322.
- Griffioen, M.; Honders, M.W.; Meijden, E.D. van der; Luxemburg-Heijs, S.A.P. van; Lurvink, E.G.A.; Kester, M.G.D.; Bergen, C.A.M. van & Falkenburg, J.H.F. (2012), Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity, Haematologica 97(8): 1196-1204.
- Pont, M.J.; Honders, M.W.; Kremer, A.N.; Lurvink, E.G.A.; Luxemburg-Heijs, S.A.P. van; Bergen, C.A.M. van; Falkenburg, J.H.F. & Griffioen, M. (2012), Rapid analysis and selection of antigens with clinical relevance for T cell therapy of hematological malignancies by microarray gene expression analysis, Immunology 137: 721-722.
- Amir, A.L.; Hagedoorn, R.S.; Luxemburg-Heijs, S.A.P. van; Marijt, E.W.A.; Kruisselbrink, A.B.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2012), Identification of a Coordinated CD8 and CD4 T Cell Response Directed Against Mismatched HLA Class I Causing Severe Acute Graft-versus-Host Disease, Biology of Blood and Marrow Transplantation 18(2): 210-219.
- Jolink, H.; Hagedoorn, R.S.; Dissel, J.T. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2012), T cells specific for the Aspergillus proteins Crf1 and catalase1 develop in patients recovering from invasive aspergillosis, Immunology 137: 734-734.
- Loenen, M.M. van; Boer, R. de; Liempt, P.A.G. van; Hagedoorn, R.S.; Meij, P.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2012), A good manufacturing practice procedure to generate therapeutic numbers of highly pure anti-leukemic virus-specific T-cells, Immunology 137: 686-686.
- Zouwen, B. van der; Kruisselbrink, A.B.; Jordanova, E.S.; Rutten, C.E.; Borne, P.A.V.; Falkenburg, J.H.F. & Jedema, I. (2012), Alloreactive Effector T Cells Require the Local Formation of a Proinflammatory Environment to Allow Crosstalk and High Avidity Interaction with Nonhematopoietic Tissues to Induce GVHD Reactivity, Biology of Blood and Marrow Transplantation 18(9): 1353-1367.
- Hobo, W.; Norde, W.J.; Schaap, N.; Fredrix, H.; Maas, F.; Schellens, K.; Falkenburg, J.H.F.; Korman, A.J.; Olive, D.; Voort, R. van der & Dolstra, H. (2012), B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8(+) T Cells in Patients After Allogeneic Stem Cell Transplantation, Journal of Immunology 189(1): 39-49.
- Maas, F.; Hobo, W.; Norde, W.J.; Fredrix, H.; Falkenburg, J.H.F.; Korman, A.J.; Schaap, N.; Olive, D.; Voort, R. van der & Dolstra, H. (2012), B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+T cells in patients after allogeneic stem cell transplantation, Immunology 137: 602-602.
- Meij, P.; Jedema, I.; Hoorn, M.A.W.G. van der; Bongaerts, R.; Cox, L.; Wafelman, A.R.; Marijt, E.W.A.; Willemze, R. & Falkenburg, J.H.F. (2012), Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study, Haematologica 97(8): 1205-1208.
- Zouwen, B. van der; Kruisselbrink, A.B.; Falkenburg, J.H.F. & Jedema, I. (2012), Haematopoiesis- specific T-cells may induce GvHD via induction of collateral damage to non-haematopoietic cells, Bone Marrow Transplantation 47: S313-S314.
- Loenen, M.M. van; Boer, R. de; Hagedoorn, R.S.; Jankipersadsing, V.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2012), Multicistronic vector encoding optimized safety switch for adoptive therapy with TCR-modified T-cells, Immunology 137: 689-689.
- Lam, T.S.; Meent, M. van de; Falkenburg, J.H.F. & Jedema, I. (2012), Naive T cells showing HLA-restricted reactivity against unpulsed autologous dendritic cells hamper enrichment by in vitro priming of low-frequency antigen-specific T cells, Immunology 137: 716-717.
- Falkenburg, F. (2012), Separating graft versus host from graft versus leukemia reactivity, Onkologie 35: 29-29.
- Passweg, J.R.; Baldomero, H.; Gratwohl, A.; Bregni, M.; Cesaro, S.; Dreger, P.; Witte, T. de; Farge-Bancel, D.; Gaspar, B.; Marsh, J.; Mohty, M.; Peters, C.; Tichelli, A.; Velardi, A.; Elvira, C.R. de; Falkenburg, F.; Sureda, A.; Madrigal, A. & European Grp Blood Marrow (2012), The EBMT activity survey: 1990-2010, Bone Marrow Transplantation 47(7): 906-923.
- Jahn, L.; Hombrink, P.; Hassan, C.; Kester, M.G.D.; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2012), Two step selection protocol based on the expression of T cell activation marker CD137 increases efficacy in generating high-affinity allo-HLA restricted T cells, Immunology 137: 724-724.
- Hombrink, P.; Hassan, C.; Kester, M.G.D.; Bergen, C.A.M. van; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2011), HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens, Blood 118(21): 1725-1725.
- Nijveen, H.; Kester, M.G.D.; Hassan, C.; Viars, A.; Ru, A.H. de; Jager, M. de; Falkenburg, J.H.F.; Leunissen, J.A.M. & Veelen, P.A. van (2011), HSPVdb-the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands, Immunogenetics 63(3): 143-153.
- Boer, M.G.J. de; Jolink, H.; Halkes, C.J.M.; Heiden, P.L.J. van der; Kremer, D.; Falkenburg, J.H.F.; Vosse, E. van de & Dissel, J.T. van (2011), Influence of Polymorphisms in Innate Immunity Genes on Susceptibility to Invasive Aspergillosis after Stem Cell Transplantation, PLoS ONE 6(4).
- Stevanovic, S.; Schie, M.L.J. van; Griffioen, M. & Falkenburg, J.H.F. (2011), HLA Class II Disparity Is Necessary and Sufficient for Induction of Effective Anti-Tumor Immunity by Donor Lymphocyte Infusion in a NOD/Scid Mouse Model for Human Acute Lymphoblastic Leukemia, Blood 118(21): 296-296.
- Stevanovic, S.; Griffioen, M.; Nijmeijer, B.A.; Schie, M.L.J. van; Stumpf, A.N.; Rutten, C.E.; Willemze, R. & Falkenburg, J.H.F. (2011), Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia., Leukemia.
- Broen, K.; Levenga, H.; Vos, J.; Bergen, K. van; Fredrix, H.; Greupink-Draaisma, A.; Kester, M.; Falkenburg, J.H.F.; Mulder, P. de; Witte, T. de; Griffioen, M. & Dolstra, H. (2011), A Polymorphism in the Splice Donor Site of ZNF419 Results in the Novel Renal Cell Carcinoma-Associated Minor Histocompatibility Antigen ZAPHIR, PLoS ONE 6(6).
- Navarrete, M.A.; Heining-Mikesch, K.; Schuler, F.; Bertinetti-Lapatki, C.; Ihorst, G.; Keppler-Hafkemeyer, A.; Dolken, G. & Veelken, H. (2011), Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma, Blood 117(5): 1483-1491.
- Christopoulos, P.; Pfeifer, D.; Bartholome, K.; Follo, M.; Timmer, J.; Fisch, P. & Veelken, H. (2011), Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL, Blood 117(14): 3836-3846.
- Warncke, M.; Buchner, M.; Thaller, G.; Dodero, A.; Bulashevska, A.; Pfeifer, D.; Timmer, J. & Veelken, H. (2011), Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells, Cancer Immunology, Immunotherapy 60(1): 49-60.
- Jedema, I.; Meent, M. van de; Pots, J.; Kester, M.G.D.; Beek, M.T. van der & Falkenburg, J.H.F. (2011), Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells, Haematologica 96(8): 1204-1212.
- Zandvliet, M.L.; Liempt, E. van; Jedema, I.; Kruithof, S.; Kester, M.G.D.; Guchelaar, H.J.; Falkenburg, J.H.F. & Meij, P. (2011), Simultaneous Isolation of CD8(+) and CD4(+) T Cells Specific for Multiple Viruses for Broad Antiviral Immune Reconstitution After Allogeneic Stem Cell Transplantation, Journal of Immunotherapy 34(3): 307-319.
- Amir, A.L.; Steen, D.M. van der; Loenen, M.M. van; Hagedoorn, R.S.; Boer, R. de; Kester, M.D.G.; Ru, A.H. de; Lugthart, G.J.; Kooten, C. van; Hiemstra, P.S.; Jedema, I.; Griffioen, M.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2011), PRAME-Specific Allo-HLA-Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer, Clinical Cancer Research 17(17): 5615-5625.
- Falkenburg, J.H.F. (2011), PR1 on the edge of humoral immunotherapy, Blood 117(16): 4164+.
- Norde, W.J.; Maas, F.; Hobo, W.; Korman, A.; Quigley, M.; Kester, M.G.D.; Hebeda, K.; Falkenburg, J.H.F.; Schaap, N.; Witte, T.M. de; Voort, R. van der & Dolstra, H. (2011), PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation, Cancer Research 71(15): 5111-5122.
- Norde, W.J.; Maas, F.; Korman, A.; Quigley, M.; Kester, M.; Hebeda, K.; Falkenburg, J.H.F.; Witte, T. de; Schaap, N.; Voort, R. van der & Dolstra, H. (2011), PD-1/PD-L1 interactions contribute to functional impairment of minor histocompatibility antigen-specific CD8+T-cells targeting PD-L1-expressing leukaemic cells, Bone Marrow Transplantation 46: S310S310.
- Loenen, M.M. van; Boer, R. de; Hagedoorn, R.S.; Egmond, E.H.M. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2011), Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies, Haematologica 96(3): 477-481.
- Bishop, M.R.; Alyea, E.P.; Cairo, M.S.; Falkenburg, J.H.F.; June, C.H.; Kroger, N.; Little, R.F.; Miller, J.S.; Pavletic, S.Z.; Porter, D.L.; Riddell, S.R.; Besien, K. van; Wayne, A.S.; Weisdorf, D.J.; Wu, R.S. & Giralt, S. (2011), National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee, Biology of Blood and Marrow Transplantation 17(4): 443-454.
- Jedema, I.; Dreunen, L. van; Hagedoorn, R.S. & Falkenburg, J.H.F. (2011), MULTI-DIMENSIONAL RESISTANCE PHENOTYPE ALLOWS QUIESCENT LEUKEMIC STEM CELLS RESIDING AFTER TYROSINE KINASE INHIBITOR TREATMENT TO ESCAPE FROM IMMUNOLOGICAL INTERVENTIONS WITH ALLOREACTIVE T CELLS AND NK CELLS, Biology of Blood and Marrow Transplantation 17(2): S245S245.
- Hombrink, P.; Hadrup, S.R.; Bakker, A.; Kester, M.G.D.; Falkenburg, J.H.F.; Borne, P.A.V.; Schumacher, T.N.M. & Heemskerk, M.H.M. (2011), High-Throughput Identification of Potential Minor Histocompatibility Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations, PLoS ONE 6(8).
- Falkenburg, J.H.F. & Warren, E.H. (2011), Graft versus Leukemia Reactivity after Allogeneic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation 17(1): S33S38.
- Jedema, I.; Lam, T.S.; Meent, M. van de; Pots, J.; Hoogstraten, C. & Falkenburg, J.H.F. (2011), DELICATE BALANCE BETWEEN REGULATION AND STIMULATION AT THE ANTIGEN PRESENTING CELL SITE DETERMINES THE LIKELIHOOD OF SUCCESSFUL IN-VITRO PRIMING AND ENRICHMENT OF LEUKEMIA-REACTIVE T CELLS FROM THE NAIVE DONOR REPERTOIRE, Biology of Blood and Marrow Transplantation 17(2): S211S211.
- Armistead, P.M.; Liang, S.D.; Li, H.; Lu, S.J.; Bergen, C.A.M. van; Alatrash, G.; John, L.S.; Hunsucker, S.A.; Sarantopoulos, S.; Falkenburg, J.H.F. & Molldrem, J.J. (2011), Common Minor Histocompatibility Antigen Discovery Based upon Patient Clinical Outcomes and Genomic Data, PLoS ONE 6(8).
- Broen, K.; Levenga, H.; Vos, J.; Bergen, K. van; Fredrix, H.; Greupink-Draaisma, A.; Kester, M.; Falkenburg, J.H.F.; Witte, T. de; Griffioen, M. & Dolstra, H. (2011), A polymorphism in the splice donor site of ZNF419 results in the novel renal cell carcinoma-associated minor histocompatibility antigen zaphir, Bone Marrow Transplantation 46: S89S89.
- Falkenburg, W.J.J.; Melenhorst, J.J.; Meent, M. van de; Kester, M.G.D.; Hombrink, P.; Heemskerk, M.H.M.; Hagedoorn, R.S.; Gostick, E.; Price, D.A.; Falkenburg, J.H.F.; Barrett, A.J. & Jedema, I. (2011), Allogeneic HLA-A*02-Restricted WT1-Specific T Cells from Mismatched Donors Are Highly Reactive but Show Off-Target Promiscuity, Journal of Immunology 187(5): 2824-2833.
- Harskamp, J.C.; Heiden, P.L.J. van der; Egmond, H.M. van; Veld, S.A.J.; Vos, H.L.; Halkes, C.J.M.; Veelken, H.; Falkenburg, J.H.F. & Marijt, E.W. (2011), T-cell chimerism does significantly bias overall chimerism status after T-cell depleted allogeneic stem cell transplantation and is influenced by immunological factors including the conditioning regimen, GvHD and CMV serostatus, Bone Marrow Transplantation 46: S204S204.
- Borne, P.A. von dem; Halkes, C.J.M.; Marijt, E.W.; Veelken, H. & Falkenburg, J.H.F. (2011), Feasibility of very low dose donor lymphocyte infusion early after T-cell depleted allogeneic stem cell transplantation, Bone Marrow Transplantation 46: S318S318.
- Bergen, C.A.M. van; Luxemburg-Heijs, S.A.P. van; Eefting, M.; Jedema, I.; Halkes, C.J.M.; Oen, M.G.; Veelken, J. & Falkenburg, J.H.F. (2011), Detailed monitoring of selective graft versus leukemia T-cell immune reactions following donor lymphocyte infusion, Bone Marrow Transplantation 46: S315S316.
- Loenen, M.M. van; Hagedoorn, R.S.; Boer, R. de; Egmond, E.H.M. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2011), Rapid Re-expression of Retrovirally Introduced Versus Endogenous TCRs in Engineered T cells After Antigen-specific Stimulation, Journal of Immunotherapy 34(2): 163-172.
- Zouwen, B. van der; Kruisselbrink, A.; Falkenburg, J.H.F. & Jedema, I. (2011), Collateral Damage of Non-Hematopoietic Tissue by Hematopoiesis-Specific T Cells Results in GvHD During An Ongoing Profound Gvl Reaction, Blood 118(21): 1722-1722.
- Jolink, H.; Oorschot, E. van; Kuijper, E.J.; Drijfhout, J.W.; Dissel, J.T.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2010), Identification of Multiple HLA Class II Epitopes of Aspergillus Fumigatus by Generation of CD4+T Cell Clones Recognizing the A. Fumigatus proteins Crf1 and Catalase1., Blood 116(21): 963-963.
- Zandvliet, M.L.; Liempt, E. van; Jedema, I.; Veltrop-Duits, L.A.; Willemze, R.; Guchelaar, H.J.; Falkenburg, J.H.F. & Meij, P. (2010), Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy, Cytotherapy 12(7): 933-944.
- Amir, A.L.; D'Orsogna, L.J.A.; Roelen, D.L.; Loenen, M.M. van; Hagedoorn, R.S.; Boer, R. de; Hoorn, M.A.W.G. van der; Kester, M.G.D.; Doxiadis, I.I.N.; Falkenburg, J.H.F.; Claas, F.H.J. & Heemskerk, M.H.M. (2010), Allo-HLA reactivity of virus-specific memory T cells is common, Blood 115(15): 3146-3157.
- Nijmeijer, B.A.; Schie, M.L.J. van; Halkes, C.J.M.; Griffioen, M.; Willemze, R. & Falkenburg, J.H.F. (2010), A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL, Blood 116(26): 5930-5940.
- Falkenburg, J.H.F. (2010), Combating cancer with allogeneic T cells, Blood 115(19): 3856-3857.
- Jedema, I.; Lam, T.S.; Meent, M. van de; Hoogstraten, C. & Falkenburg, J.H.F. (2010), Delicate balance between regulation and stimulation at the antigen presenting cell site determines the likelihood of successful priming and survival of antigen-specific T-cells from the naive donor repertoire, Bone Marrow Transplantation 45: S67S67.
- Dolstra, H.; Overes, I.; Fredrix, H.; Kester, M.; Falkenburg, J.H.F.; Voort, R. van der & Witte, T. de (2010), Efficient activation of LRH-1-specific CD8+T-cell responses from transplanted leukaemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells, Bone Marrow Transplantation 45: S298S298.
- Rutten, C.E.; Luxemburg-Heijs, S.A.P. van; Meijden, E.D. van der; Griffioen, M.; Oudshoorn, M.; Willemze, R. & Falkenburg, J.H.F. (2010), HLA-DPBI Mismatching Results in the Generation of a Full Repertoire of HLA-DPBI-Specific CD4(+) T Cell Responses Showing Immunogenicity of all HLA-DPBI Alleles, Biology of Blood and Marrow Transplantation 16(9): 1282-1292.
- Stumpf, A.N.; Meijden, E.D. van der; Willemze, R.; Falkenburg, J.H.F. & Griffioen, M. (2010), Indirect presentation HLA class II restricted minor histocompatibility antigens is a characteristic of HLA-DM resistant antigens, Bone Marrow Transplantation 45: S116S116.
- Zouwen, B. van der; Kruisselbrink, A.; Borne, P. von dem; Falkenburg, J. & Jedema, I. (2010), INDUCTION OF GVHD BY HEMATOPOIESIS-SPECIFIC T CELLS MAY OCCUR DURING AN ONGOING PROFOUND GVL REACTION DUE TO ICAM-1 MEDIATED INDUCTION OF COLLATERAL DAMAGE, Haematologica 95: 209-209.
- Bishop, M.R.; Alyea, E.P.; Cairo, M.S.; Falkenburg, J.H.F.; June, C.H.; Kroger, N.; Little, R.F.; Miller, J.S.; Pavletic, S.Z.; Porter, D.; Riddell, S.R.; Besien, K. van; Wayne, A.S.; Weisdorf, D.J.; Wu, R. & Giralt, S. (2010), Introduction to the Reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation 16(5): 563-564.
- Nijmeijer, B.; Schie, M. van; Goselink, H.; Halkes, C. & Falkenburg, J. (2010), LEUKEMIC CD52 NEGATIVE GPI DEFECTIVE CLONES ARE COMMON IN ALL, ESCAPE ALEMTUZUMAB THERAPY, BUT ARE SENSITIVE TO RITUXIMAB MEDIATED COMPLEMENT DEPENDENT CYTOTOXICITY: RATIONALE FOR COMBINATION THERAPY, Haematologica 95: 467-467.
- Loenen, M.M. van; Boer, R. de; Amir, A.L.; Hagedoorn, R.S.; Volbeda, G.L.; Willemze, R.; Rood, J.J. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2010), Mixed T cell receptor dimers harbor potentially harmful neoreactivity, Proceedings of the National Academy of Sciences 107(24): 10972-10977.
- Miller, J.S.; Warren, E.H.; Brink, M.R.M. van den; Ritz, J.; Shlomchik, W.D.; Murphy, W.J.; Barrett, A.J.; Kolb, H.J.; Giralt, S.; Bishop, M.R.; Blazar, B.R. & Falkenburg, J.H.F. (2010), NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction, Biology of Blood and Marrow Transplantation 16(5): 565-586.
- Porter, D.L.; Alyea, E.P.; Antin, J.H.; DeLima, M.; Estey, E.; Falkenburg, J.H.F.; Hardy, N.; Kroeger, N.; Leis, J.; Levine, J.; Maloney, D.G.; Peggs, K.; Rowe, J.M.; Wayne, A.S.; Giralt, S.; Bishop, M.R. & Besien, K. van (2010), NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation 16(11): 1467-1503.
- Loenen, M.M. van; Boer, R. de; Hagedoorn, R.S.; Egmond, H.M. van; Amir, A.L.; Willemze, R.; Falkenburg, J.H.F. & Heemskerk, M. (2010), Optimization of the HA-1-specific T-cell receptor for gene therapy of haematological malignancies after stem cell transplantation, Bone Marrow Transplantation 45: S65S65.
- Rutten, C.E.; Luxemburg-Heijs, S.A.P. van; Meijden, E.D. van der; Griffioen, M.; Oudshoorn, M.; Willemze, R. & Falkenburg, J.H.F. (2010), Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro, Blood 115(1): 151-153.
- Jedema, I.; Dreunen, L. van & Falkenburg, J. (2010), QUIESCENT LEUKEMIC STEM CELLS RESIDING AFTER TYROSINE KINASE INHIBITOR TREATMENT ARE NOT TARGETED BY ALLOREACTIVE T CELLS AND NK CELLS, Haematologica 95: 476-476.
- Zandvliet, M.L.; Falkenburg, J.H.F.; Liempt, E. van; Veltrop-Duits, L.A.; Lankester, A.C.; Kalpoe, J.S.; Kester, M.G.D.; Steen, D.M. van der; Tol, M.J. van; Willemze, R.; Guchelaar, H.J.; Schilham, M.W. & Meij, P. (2010), Combined CD8(+) and CD4(+) adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection, Haematologica 95(11): 1943-1951.
- Bergen, C.A.M. van; Rutten, C.E.; Meijden, E.D. van der; Luxemburg-Heijs, S.A.P. van; Lurvink, E.G.A.; Houwing-Duistermaat, J.J.; Kester, M.G.D.; Mulder, A.; Willemze, R.; Falkenburg, J.H.F. & Griffioen, M. (2010), High-Throughput Characterization of 10 New Minor Histocompatibility Antigens by Whole Genome Association Scanning, Cancer Research 70(22): 9073-9083.
- Jedema, I.; Dreunen, L. van; Hagedoorn, R.S. & Falkenburg, J.H.F. (2010), Multi-Dimensional Resistance Phenotype Allows Subpopulation of Quiescent Chronic Myeloid Leukemia Stem Cells to Universally Escape From Therapeutic Attack, Blood 116(21): 93-93.
- Heiden, P.L.J. van der; Harskamp, J.C.; Egmond, E.H.M. van; Deutz-Terlouw, P.P.; Falkenburg, J.H.F. & Marijt, E.W.A. (2010), Eradication of Recipient CMV Specific T Cells by Donor Lymphocyte Infusion Does Not Impair Protective Immunity In Patients Transplanted with a CMV Negative Donor Due to An Early Donor Derived Primary CMV Specific T Cell Response, Blood 116(21): 363-363.
- Klnkenberg, R.E.; Griffioen, M.; Meijden, E.D. van der; Marijt, E.W.A. & Falkenburg, J.H.F. (2010), Primary Antibody Responses Against the Novel Pandemic H1N1 and Secondary Antibody Responses Against Seasonal H1N1 Can Be Induced by Vaccination In Patients Early After Allogeneic Stem Cell Transplantation, Blood 116(21): 545-545.
- Papaioannou, D.; Strothmeyer, A.M.; Duhren-von Minden, M.; Navarrete, M.A.; Zirlik, K.; Heining-Mikesch, K. & Veelken, H. (2010), HLA-Dependent Immune Selection Pressure on the Idiotype-Is Predominantly Driven by Somatic Hypermutation In Malignant Lymphoma but Also Modulates Vh Usage In Normal B Cells, Blood 116(21): 1290-1290.
- Harskamp, J.C.; Heiden, P.L.J. van der; Egmond, E.H.M. van; Veld, S.A.J.; Vos, H.L.; Halkes, C.J.M.; Falkenburg, J.H.F. & Marijt, E.W.A. (2010), T Cell Chimerism After T Cell Depleted Allogeneic Stem Cell Transplantation Is Influenced by Immunological Factors Including the Conditioning Regimen, CMV Serostatus and GvHD and Does Significantly Bias Overall Chimerism Status, Blood 116(21): 566-566.
- Borne, P.A. von dem; Halkes, C.J.M.; Starrenburg, C.W.J.; Marijt, W.A.F. & Falkenburg, J.H.F. (2010), Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft., Blood 116(21): 961-962.
- Halkes, C.J.M.; Jedema, I.; Wolbers, J.O.; Egmond, E.M. van; Borne, P.A. von dem; Marijt, E.W.A.F. & Falkenburg, J.H.F. (2010), Low Incidence of Post-Transplant EBV-Related Disease After Alemtuzumab-Mediated T Cell Depletion Is Explained by the Differential Susceptibility to Alemtuzumab of B Cells and Protective CD8 and CD4 T Cells., Blood 116(21): 962-963.
- van der Veken LT, Campelo MD, van der Hoorn MAWG, Hagedoorn RS, van Egmond HME, van Bergen J, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Functional Analysis of Killer Ig-Like Receptor-Expressing Cytomegalovirus-Specific CD8(+) T Cells, Journal of Immunology 182(1): 92-101.
- van der Veken LT, Coccoris M, Swart E, Falkenburg JHF, Schumacher TN & Heemskerk MHM (2009), alpha beta T Cell Receptor Transfer to gamma delta T Cells Generates Functional Effector Cells without Mixed TCR Dimers In Vivo, Journal of Immunology 182(1): 164-170.
- van der Heiden PLJ, de Boer R, van der Steen DM, Kester MGD, van der Hoorn MWAG, Haarman WME, Barnby-Porritt HE, Fry JW, Napper CE, Marijt EWA, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Identification of Varicella-Zoster Virus-Specific CD8 T Cells in Patients after T-Cell-Depleted Allogeneic Stem Cell Transplantation, Journal of Virology 83(14): 7361-7364.
- Falkenburg WJJ, Melenhorst JJ, Kester MGD, Hombrink P, Heemskerk MHM, Gostick E, Price DA, Falkenburg JHF, Barrett AJ & Jedema I (2009), Allogeneic HLA-A2-Restricted WT1-Specific T Cells From Mismatched Donors Are Highly Reactive but Show Potentially Hazardous Promiscuity, Blood 114(22): 1565-1565.
- van der Zouwen B, Kruisselbrink AB, Borne PAV, Willemze R, Falkenburg JHF & Jedema I (2009), Collateral Damage: a Mechanism for Hematopoiesis-Restricted Mhag-Specific T Cells to Play a Role in the Effector Phase of GvHD., Blood 114(22): 1377-1378.
- Griffioen M, Honders MW, Stumpf AN, van der Meijden ED, van Bergen CAM, van Luxemburg-Heijs SAP, Lurvink EGA, Willemze R & Falkenburg JHF (2009), Diversity of HLA Class I and Class II Restricted Minor Histocompatibility Antigens in Graft-Versus-Leukemia Reactivity, Blood 114(22): 1566-1567.
- van Loenen MM, Hagedoorn RS, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Extracellular Domains of CD8a and beta Subunits Are Required and Sufficient for HLA Class I Restricted Helper Activity of TCR-Engineered CD4(+) T Cells., Blood 114(22): 1385-1385.
- Nijimeijer BA, Szuhai K, Goselink HM, van Schie MLJ, van der Burg M, de Jong D, Marijt EW, Ottrnann OG, Willemze R & Falkenburg JHF (2009), Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors, Experimental Hematology 37(3): 376-385.
- Amir AL, van der Steen DM, Hagedoorn RS, Griffioen M, Falkenburg JHF & Heemskerk MHM (2009), High Avidity PRAME Specific T Cells Derived From In Vivo HLA Mismatched Transplantation Setting Potentially Useful for Immunotherapeutic Strategies., Blood 114(22): 1568-1568.
- van Bergen CAM, van der Meijden ED, Rutten CE, van Luxemburg SAP, Lurvink EGA, Honders MW, Houwing JJ, Sampietro ML, Willemze R, Falkenburg JHF & Griffioen M (2009), High Throughput Minor Histocompatibility Antigen Discovery by Whole Genome Association Scanning, Blood 114(22): 287-287.
- Zandvliet ML, Falkenburg JHF, Jedema I, Willemze R, Guchelaar HJ & Meij P (2009), Detailed Analysis of IFNg Response Upon Activation Permits Efficient Isolation of Cytomegalovirus-specific CD8(+) T Cells for Adoptive Immunotherapy, Journal of Immunotherapy 32(5): 513-523.
- Stevanovic S, Nijmeijer B, Van Schie MLJ, Willemze R, Griffioen M & Falkenburg JHF (2009), Human T Cells with Distinct Specificities Mediate Graft-Versus-Leukemia Reactivity and Xenogeneic Graft-Versus-Host Disease in a NOD/Scid Mouse Model for Human Acute Leukemia., Blood 114(22): 544-544.
- Nijmeijer B, Van Schie MLJ, Goselink HM, Willemze R & Falkenburg JHF (2009), Leukemic CD52 Negative Subclones Due to Defective Glycophosphatidyl-Innositol Anchoring Are Common in Acute Precursor B Lymphoblastic Leukemia, Escape Alemtuzumab Therapy, but Display Increased Sensitivity to Rituximab Mediated Complement Dependent Cytotoxicity: a Mechanistic Rationale for Antibody Combination Therapy, Blood 114(22): 344-344.
- Overes IM, Fredrix H, Kester MGD, Falkenburg JHF, van der Voort R, de Witte TM & Dolstra H (2009), Efficient Activation of LRH-1-specific CD8(+) T-cell Responses From Transplanted Leukemia Patients by Stimulation With P2X5 mRNA-electroporated Dendritic Cells, Journal of Immunotherapy 32(6): 539-551.
- van Loenen MM, Hagedoorn RS, de Boer R, van Egmond EM, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Optimization of the HA-1-Specific T Cell Receptor for Gene Therapy of Hematological Malignancies., Blood 114(22): 1570-1570.
- van der Zouwen B, Kruisselbrink AB, Borne PAV, Willemze R, Falkenburg JHF & Jedema I (2009), Potent Alloreactive Effector T Cells Cause Limited Damage to Non-Hematopoietic Tissues Under Non-Inflammatory Conditions, Despite Proper Expression of the Relevant Target Antigens., Blood 114(22): 968-968.
- Jedema I, van Dreunen L, Willemze R & Falkenburg JHF (2009), Treatment with Tyrosine Kinase Inhibitors May Impair the Potential Curative Effect of Allogeneic Stern Cell Transplantation, Blood 114(22): 352-353.
- Aslanyan MG, Langemeijer SMC, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Zadro R, Batinic D, Amadori S, Lo Coco F, Scheele T, Kroeze L, Massop M, van Hoogen P, Stevens E, Muus P, Suciu S, Baila L, Marijt EWA, Willemze R, de Witte T, van der Reijden B & Jansen JH (2009), Incidence and Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Treated within the EORTC/GIMEMA AML-12/06991 AML Trial., Blood 114(22): 1023-1024.
- Griffioen M, Stumpf AN, Honders MW, van der Meijden ED, van Luxemburg-Heijs SAP, van Bergen CAM, Willemze R & Falkenburg JHF (2009), DIVERSITY AND DIFFERENTIAL INVOLVEMENT OF HLA CLASS I AND II RESTRICTED MINOR HISTOCOMPATIBILITY ANTIGENS IN GRAFT-VERSUS-LEUKEMIA REACTIVITY, Haematologica 94: 54-54.
- Jedema I, Pots J, van de Meent M, Willemze R & Falkenburg JHF (2009), The absolute number as well as the activation kinetics of regulatory T-cells determines the successful generation of primary anti-tumour and pathogen-specific immune responses from the naive donor T-cell repertoire, Bone Marrow Transplantation 43: S52S53.
- van Loenen MM, Hagedoorn RS, Kester NGD, Hoogeboom M, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Kinetic Preservation of Dual Specificity of Coprogrammed Minor Histocompatibility Antigen-Reactive Virus-Specific T Cells, Cancer Research 69(5): 2034-2041.
- Falkenburg JHF, Stumpf A, Rutten CE, van der Meijden ED, Luxemburg-Heijs SAP, van Bergen CAM, Willemze R & Griffioen M (2009), TARGETING OF HLA CLASS II RESTRICTED ANTIGENS IN GRAFT VERSUS LEUKEMIA REACTIVITY, Biology of Blood and Marrow Transplantation 15(2): 114-114.
- Griffioen M, van Egmond EHM, Kester MGD, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy, Haematologica 94(9): 1316-1320.
- Norde WJ, Overes IM, Maas F, Fredrix H, Vos JCM, Kester MGD, van der Voort R, Jedema I, Falkenburg JHF & Schattenberg AV (2009), Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells, Blood 113(10): 2312-2323.
- von dem Borne PA, Starrenburg CWJ, Marijt WAF, Halkes CJM, Falkenburg JHF & Willemze R (2009), Allogeneic stem cell transplantation for multiple myeloma with a T-cell depleted reduced-intensity conditioning regimen using both unrelated and related donors, Bone Marrow Transplantation 43: S17S18.
- van Bergen CAM, van der Meijden ED, van Luxemburg SAP, Lurvink EGA, Rutten CE, Houwing JJ, Sampietro ML, Halkes CJM, Willemze R, Falkenburg JHF & Griffioen M (2009), HIGH THROUGHPUT IDENTIFICATION OF MINOR HISTOCOMPATIBILITY ANTIGENS BY WHOLE GENOME ASSOCIATION SCANNING, Haematologica 94: 224-224.
- Jedema L, van Dreunen L, Willemze R & Falkenburg JHF (2009), IMATINIB AND DASATINIB TREATMENT RESULTS IN SELECTION OF A POPULATION OF QUIESCENT LEUKEMIC STEM CELLS SHOWING CROSS-RESISTANCE TO CELLULAR IMMUNOTHERAPEUTIC INTERVENTIONS, Haematologica 94: 441-441.
- D'Orsogna L, Amir A, Zoet Y, van Miert P, van der Meer-Prins E, Kester M, Falkenburg F, Heemskerk M, Doxiadis I & Roelen D (2009), New Tools To Monitor the Impact of Viral Infection on the Alloreactive T-Cell Repertoire., American Journal of Transplantation 9: 478-478.
- Dorsogna L, Amir A, Zoet Y, van Miert P, van der Meer-Prins E, Kester M, Falkenburg F, Heemskerk M, Doxiadis I & Roelen D (2009), New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire, Tissue Antigens 73(5): 387-387.
- Amir A, Dorsogna L, van Loenen M, Kester M, Doxiadis I, Roelen D, Falkenburg F, Heemskerk M & Claas F (2009), Alloreactivity of virus specific memory T-cells is common, Tissue Antigens 73(5): 385-385.
- Stumpf AN, van der Meijden ED, van Bergen CAM, Willemze R, Falkenburg JHF & Griffioen M (2009), Identification of four new HLA class II restricted minor histocompatibility antigens as haematopoietic targets in anti-tumour immunity, Bone Marrow Transplantation 43: S73S73.
- Stevanovic S, Griffioen M, Nijmeijer BA, Van Schie MLJ, Willemze R & Falkenburg JHF (2009), Human alloreactive CD4+T-cells as potent effector cells and sole mediators of anti-tumour responses in a NOD/Scid mouse model for human acute leukaemia, Bone Marrow Transplantation 43: S263S263.
- Stumpf AN, van der Meijden ED, van Bergen CAM, Willemze R, Falkenburg JHF & Griffioen M (2009), Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity, Blood 114(17): 3684-3692.
- Rutten CE, van Luxemburg-Heijs SAP, van der Meijden ED, Griffioen M, Willemze R & Falkenburg JHF (2009), HLA-DPB1 mismatching results in the generation of a full repertoire of HLA-DPB1 specific CD4+T-cell responses showing immunogenicity of all HLA-DP alleles, Bone Marrow Transplantation 43: S78S79.
- Amir AL, D'Orsogna LJ, van Loenen MM, Kester M, Roelen DL, Doxiadis II, Falkenburg F, Heemskerk M & Claas FH (2009), Alloreactivity of Virus Specific Memory T-Cells., American Journal of Transplantation 9: 361-361.
- Griffioen M, van Egmond HME, Barnby-Porritt H, van der Hoorn MAWG, Hagedoorn RS, Kester MGD, Schwabe N, Willemze R, Falkenburg JHF & Heemskerk MHM (2008), Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application, Haematologica 93(10).
- Borne PAVD, Starrenburg CWJI, Beaumont MF, Halkes SJM, Marijt EWA, Falkenburg JHF & Willemze R (2008), The Effect of Donor Lymphocyte Infusion Dose on the Occurrence of Severe Life-Threatening Acute Graft-Versus-Host Disease Early after Reduced Intensity Conditioning T Cell Depleted Stem Cell Transplantation., Blood 112(11): 773-773.
- Baeumler J, Szuhai K, Falkenburg JHF, van Schiec MLJ, Ottmann OG & Nijmeijer BA (2008), Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement, Cancer Genetics and Cytogenetics 185(1).
- Zandvliet ML, Falkenburg JHF, Kester MGD, de Ru AH, van Veelen PA, Willemze R, Guchelaar HJ & Meij P (2008), Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation, Blood 112(11): 1330-1331.
- Zandvliet ML, Falkenburg JHF, Jedema I, Willemze R, Guchelaar HJ & Meij P (2008), Universal CD137 Expression upon Activation Allows Efficient Isolation of a Broad Repertoire of Virus-Specific CD8+and CD4+T Cells for Adoptive Immunotherapy, Blood 112(11): 774-775.
- Zandvliet ML, Falkenburg JHF, Veltrop-Duits LA, Schilham MW, Willemze R, Guchelaar HJ & Meij P (2008), Generation of Combined CD8+and CD4+T Cell Lines with High Specificity for Adenovirus Hexon Epitopes for Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation, Blood 112(11): 775-776.
- Amir A, Hagedoorn RS, Marijt EAF, Willenize R, Falkenburg JHF & Heewskerk MHM (2008), LEUKEMIC BLASTS ACTING AS HOST ANTIGEN PRESENTING CELLS TRIGGER A COMBINED CD4 AND CD8 ALLO-IMMUNE RESPONSE DIRECTED AGAINST MISMATCHED HLA CLASS I, Biology of Blood and Marrow Transplantation 14(2): 136-136.
- Falkenburg JHF, Heslop HE & Barrett AJ (2008), T cell therapy in allogeneic stem cell transplantation, Biology of Blood and Marrow Transplantation 14(1).
- Marijt WA, von dem Borne A, Barge MY, Deutz-Terlouw P, Beaumont M, Starrenburg CWJ, Fibbe E, Willemze R & Falkenburg JHF (2008), DONOR LYMPHOCYTE INFUSION FOR MIXED CHIMERISM AT 7 MONTHS AFTER T CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION REDUCES RELAPSE RISK, Haematologica 93: 241-241.
- Borne PAVD, Starrenburg CW, Barge RM, Marijt EW, Falkenburg JHF & Willemze R (2008), Comparable engraftment and chimerism kinetics using oral and intravenous fludarabine as part of a reduced intensity conditioning regimen, Bone Marrow Transplantation 42(2).
- Rutten CE, van Luxemburg-Heijs SAP, Griffioen M, Marijt EWA, Jedema I, Heemskerk MHM, Posthuma EFM, Willemze R & Falkenburg JHF (2008), HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia, Leukemia 22(7).
- Griffioen M, van der Meijdent ED, Slager EH, Honders MW, Rutten CE, van Luxemburg-Heijs SAP, von dem Borne PA, van Rood JJ, Willemze R & Falkenburg JHF (2008), Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity, Proceedings of the National Academy of Sciences 105(10).
- Rutten CE, van Luxemburg-Heijs SAP, Griffioen M, Marijt WAE, Jedema I, Heemskerk MHM, Posthuma FM, Willemze R & Falkenburg JH (2008), HLA-DP AS SPECIFIC TARGET FOR GRAFT VERSUS LEUKEMIA REACTIVITY IN HLA-CLASS II EXPRESSING HEMATOLOGICAL MALIGNANCIES, Haematologica 93: 351-352.
- Heemskerk MHM, Griffioen M & Falkenburg JHF (2008), T-cell receptor gene transfer for treatment of leukemia, Cytotherapy 10(2).
- Rutten CE, van Luxemburg-Heijs SAP, von dem Borne PA, Willemze R & Falkenburg JHF (2008), The balance between graft-versus-leukemia reactivity and graft-versus-host disease is determined both by minor histocompatibity antigen expression and the presence of inflammatory cytokines in target tissues, Bone Marrow Transplantation 41.
- Overes I, Norde W, Maas F, Vos J, Van Horssen-Zoetbrood A, Fredrix H, Kester M, Van der Voort R, Jedema I, Falkenburg J, Schattenberg A, De Witte T & Dolstra H (2008), Human CD34+ myeloid leukaemic progenitor cells are susceptible to lysis by minor histocompatibility antigen LRH-1-specific cytotoxic T lymphocytes, Bone Marrow Transplantation 41.
- Jedema I, De Meent MV, Van der Heiden PLJ, Marijt WAF, Meij P, Willemze R & Falkenburg JHF (2008), Efficient induction and isolation of primary CMV-specific CD8+ T-cell responses from CMV seronegative donors for the treatment of serious CMV-related complications in CMV seropositive patients transplanted with a CMV seronegative donor, Bone Marrow Transplantation 41.
- Marijt W, Baas I, von dem Borne P, Barge R, Deutz P, Beaumont F, Starrenburg I, Fibbe W, Willemze R & Falkenburg J (2008), Prevention of relapse by donor lymphocyte infusion for mixed chimerism 7 months after T-cell depleted allogeneic stem cell transplantation, Bone Marrow Transplantation 41.
- Griffioen M, van Egmond HM, Barnby-Porritt H, van der Hoorn MAWG, Hagedoorn RS, Kester MGD, Schwabe N, Willemze R, Falkenburg JHF & Heemskerk MHM (2008), Genetic engineering of virus specific T-cells with T-cell receptors recognising minor histocompatibility antigens for clinical application, Bone Marrow Transplantation 41.
- Borne PAVD, Starrenburg CW, Marijt EW, Halkes CW, Falkenburg JH & Willemze R (2008), Donor lymphocyte infusion after reduced-intensity T-cell depleted stem cell transplantation induces conversion to full donor chimerism in most patients combined with graft-versus tumour responses and limited graft-versus-host disease, Bone Marrow Transplantation 41.
- Griffioen M, van der Meijden ED, Honders MW, Rutten C, van Luxemburg-Heijs SAP, Borne PAVD, Willemze R & Falkenburg JHF (2008), Identification of phosphatidylinositol 4-kinase type II beta as HLA class II associated minor histocompatibility antigen involved in graft-versus-leukaemia reactivity, Bone Marrow Transplantation 41.
- Rutten CE, van Luxemburg-Heijs SAP, Griffioen M, Marijt EWA, Jedema I, Heemskerk MHM, Posthuma EFM, Willemze R & Falkenburg JHF (2008), HLA-DP as specific target for graft versus leukaemia reactivity in HLA-class II expressing haematological malignancies, Bone Marrow Transplantation 41.
- Jedema I, van de Meeent M, van der Heiden PLJ, Marijit EWA, Meij P, Willemze R & Falkenburg JHF (2008), EFFICIENT INDUCTION AND ISOLATION OF A PRIMARY CMV-SPECIFIC CD8+T CELL RESPONSE FROM CMV SERONEGATIVE DONORS FOR THE TREATMENT OF SERIOUS CMV-RELATED COMPLICATIONS IN CMV SEROPOSITIVE PATIENTS TRANSPLANTED WITH A CMV SERONEGATIVE DONOR, Biology of Blood and Marrow Transplantation 14(2): 104-105.
- Amir AL, Hagedoorn RS, Marijt WAF, Willemze R, Falkenburg JHF & Heemskerk MHM (2008), Leukaemic blasts acting as host antigen presenting cells trigger a combined CD4 and CD8 allo-immune response directed against mismatched HLA class I, Bone Marrow Transplantation 41.
- von dem Borne PA, Starrenburg CW, Marijt EW, Falkenburg JHF & Willemze R (2007), Comparable engraftment and chimerism kinetics between oral and intravenous fludarabine as part of a nonmyeloablative conditioning regimen, Bone Marrow Transplantation 39.
- Amir A, Griffioen M, Kester MDG, Honders MW, Willemze R, Falkenburg JHF & Heemskerk M (2007), Allo-HLA reactive CD8 T-Cells may recognize tissue specific peptides explaining tissue restricted GVHD after HLA mismatched SCT, Blood 110(11).
- Jedema I, De Meent MV, Van der Heiden PLJ, Marijt EWA, Meij P, Willemze R & Falkenburg JHF (2007), Efficient induction and isolation of CMV-specific CD8+ T cells from CMV seronegative donors for the treatment of CMV reactivation in CMV seropositive patients transplanted with a CMV seronegative donor, Blood 110(11).
- Van der Heiden PLJ, Kester M, Van der Hoom MWAG, Haarman WME, Barnby-Porritt HE, Banaszek A, Napper CE, Marijt EWA, Willemze R, Falkenburg JHF & Heemskerk M (2007), Detection of varicella zoster virus specific CD8 T cells in patients after T cell depleted allogeneic stem cell transplantation by a novel epitope screening technology, Blood 110(11).
- Borne PAVD, Starrenburg I, Marijt EWA, Halkes S, Falkenburg JHF & Willemze R (2007), Donor lymphocyte infusion for mixed chimerism or residual disease after reduced-intensity T Cell depleted stem cell transplantation results in conversion to full donor chimerism combined with graft versus tumor responses and limited GVHD, Blood 110(11).
- Griffioen M, van der Meijden ED, Honders MW, Rutten C, van Luxemburg-Heijs SP, Borne PAVD, Willemze R & Falkenburg JHF (2007), Identification of phosphatidylinositol 4-kinase type II beta as the first HLA class II associated minor histocompatibility antigen involved in graft versus leukemia reactivity, Blood 110(11).
- Jedema I, van Dreunen L, van Loenen MM, Heemskerk M, Willemze R & Falkenburg JHF (2007), Vigorous priming of minor histocompatibility antigen specific T cells by frequent high dose peptide vaccination may lead to prolonged T cell receptor downregulation, impaired T cell functionality, and promotion of tumor escape, Blood 110(11).
- van Loenen M, Hagedoom R, van Egmond E, Willemze R, Falkenburg JHF & Heeraskerk M (2007), Physiological non-responsiveness and absence of activation induced cell death, of T cells rapidly re-expressing retrovirally-introduced TCRs after T cell activation, Blood 110(11).
- Griftioen M, van Egmond HME, van der Hoorn MAG, Hagedoorn RS, Kester M, Willemze R, Falkenburg JHF & Heemskerk M (2007), T cell receptor gene transfer to virus-specific T cells for cellular anti-tumor immunotherapy, Blood 110(11).
- Nijmeijer B, van Schie MLJ, Willemze R & Falkenburg JHF (2007), Rituximab and alemtuzumab in combination, but not alone, induce complete remissions in a preclinical animal model of primary human ALL: Rationale for combination treatment, Blood 110(11).
- Goselink HM, Nijmeijer BA, Hokke CH, van der Heijden R, Willemze R & Falkenburg JHF (2007), Proliferation of acute lymphoblastic leukemic (ALL) cells is dependent on exogenous purine administration, Blood 110(11).
- Bimmler J, Falkenburg JHF, van Schie MLJ, Szuhai K, Pape M, Droll S, Ottmann OG & Nijmeijer B (2007), Establishment and characterization of a tel/abl rearrangement responsible for imatinib sensitivity in ber/abl negative acute lymphoblastic leukemia, Blood 110(11).
- Amir A, Hagendoorn RS, Marijt EWA, Willemze R, Falkenburg JHF & Heemskerk M (2007), Leukemic blasts acting as host antigen presenting cells trigger a combined CD4 and CD8 allo-immune response directed against mismatched HLA class I, Blood 110(11).
- Meij P, Zandvliet ML, van der Heiden PLJ, Jedema I, Egmond EM, Cox LMP, de Meent MV, Bongaerts R, Hoogstraten C, Guchelaar HJ, Willemze R & Falkenburg JHF (2007), Generation and administration of CMV pp65-specific donor T-cell lines for treatment of CMV reactivation after allogeneic stem cell transplantation, Bone Marrow Transplantation 39.
- de Vries JF, von dem Borne PA, van Luxemburg-Heijs SAP, Heemskerk MHM, Willemze R, Falkenburg JHF & Barge RMY (2007), Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing, Haematologica 92(12).
- Jedema I, Meij P, Steeneveld E, Wolbers JO, van de Meent M, Smit W, Willemze R & Falkenburg JHF (2007), Efficient induction and isolation of leukaemia-reactive T-cells for adoptive transfer from naive donor T-cells, Bone Marrow Transplantation 39.
- Oosten LEM, Blokland E, Kester MGD, Falkenburg JHF, van Halteren AGS & Goulmy E (2007), Promiscuity of the alloHLA-A2 restricted T cell repertoire hampers the generation of minor histocompatibility antigen-specific cytotoxic T cells across HLA barriers, Biology of Blood and Marrow Transplantation 13(2).
- Jedema I, Meij P, Steeneveld E, Hoogendoorn M, Nijmeijer BA, van de Meent M, van Luxemburg-Heijs SAP, Willemze R & Falkenburg JHF (2007), Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay, Clinical Cancer Research 13(2).
- Hoogendoorn M, Jedema I, Barge RMY, van Luxemburg SAP, Beaumont HF, Marijt EWA, Willemze R & Falkenburg JHF (2007), Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning, Leukemia 21(12).
- Schimmel KJM, Nijmeijer BA, van Schie MLJ, Falkenburg JHF & Guchelaar HJ (2007), Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia, Leukemia Research 31(11).
- Heemskerk MHM, Hagedoorn RS, van der Hoorn MAWG, van der Veken LT, Hoogeboom M, Kester MGD, Willemze R & Falkenburg JHF (2007), Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex, Blood 109(1).
- van Bergen CAM, Kester MGD, Jedema I, Heemskerk MHM, van Luxemburg-Heijs SAP, Kloosterboer FM, Marijt WAE, de Ru AH, Schaafsma MR, Willemze R, van Veelen PA & Falkenburg JHF (2007), Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene, Blood 109(9).
- de Vries JF, Wammes LJ, Jedema I, van Dreunen L, Nijmeijer BA, Heemskerk MHM, Willemze R, Falkenburg JHF & Barge RMY (2007), Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria, Apoptosis 12(1).
- van Loenen MM, Hagedoorn RS, Kester MGD, Hoogeboom M, Willemze R, Falkenburg JHF & Heemskerk MHM (2007), Preservation of dual specificity of coprogrammed leukemia-reactive virus-specific T cells, Human Gene Therapy 18(10).
- Griffioen M, van Egmond HME, van der Hoorn MAWG, Hagedoorn RS, Kester MGD, Willemze R, Falkenburg JHF & Heemskerk MHM (2007), T cell receptor gene transfer to virus-specific T cells for cellular anti-tumor immunotherapy, Human Gene Therapy 18(10).
- Hambach L, Nijmeijer BA, Aghai Z, van Schie MLJ, Wauben MHM, Falkenburg JHF & Goulmy E (2006), Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice, Leukemia 20(2).
- van der Veken LT, Hagedoorn RS, van Loenen MM, Willemze R, Falkenburg JHF & Heemskerk NHM (2006), alpha beta T-cell receptor engineered gamma delta T cells mediate effective antileukemic reactivity, Cancer Research 66(6).
- Hambach L, Nijmeijer BA, Drabbels JJM, Falkenburg JHF & Goulmy E (2006), Chromosomal aberrations in leukaemia cells may delete tumour target antigens of stem cell-based immunotherapy, Leukemia 20(7).
- Goselink HM, Hiemstra PS, Van Noort P, Barge RMY, Willemze R & Falkenburg JHF (2006), Cytokine-dependent proliferation of human CD34(+) progenitor cells in the absence of serum is suppressed by their progeny's production of serine proteinases, STEM CELLS 24(2).
- Kloosterboer FM, van Luxemburg-Heijs SAP, Willemze R & Falkenburg JHF (2006), Similar potential to become activated and proliferate but differential kinetics and profiles of cytokine production of umbilical cord blood T cells and adult blood naive and memory T cells, Human Immunology 67(11).
- Laurin D, Spierings E, van der Veken LT, Hamrouni A, Falkenburg JHF, Souillet G, Vermeulen C, Farre A, Galambrun C, Rigal D, Bertrand Y, Goulmy E & Eljaafari A (2006), Minor histocompatibility antigen DDX3Y induces HLA-DQ5-restricted T cell responses with limited TCR-V beta usage both in vivo and in vitro, Biology of Blood and Marrow Transplantation 12(11).
- de Vries JF, Falkenburg JHF, Willemze R & Barge RMY (2006), The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells, Haematologica 91(7).
- von dem Borne PA, Beaumont F, Starrenburg CWJI, Oudshoorn M, Hale G, Falkenburg JHF, Fibbe WE, Willemze R & Barge RMY (2006), Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab, Haematologica 91(11).
- Marijt EWA, Borne PAVD, Barge RMY, Deutz PP, Beaumont MF, Starrenburg CWJI, Fibbe WE, Willemze R & Falkenburg JHF (2006), Donor lymphocyte infusion (DLI) for mixed chimerism 6 months after T cell depleted allogeneic stem cell transplantation (TCD alloSCT) may prevent relapse., Blood 108(11).
- Griffioen M, Kessler JH, Borghi M, van Soest RA, van der Minne CE, Nouta J, van der Burg SH, Medema JP, Schrier PI, Falkenburg JHF, Osanto S & Melief CJM (2006), Detection and functional analysis of CD8(+) T cells specific for PRAME: a target for T-cell therapy, Clinical Cancer Research 12(10).
- Van Bergen CA, Kester MG, Jedema I, Heemskerk MH, Van Luxemburg SA, Kloosterboer FM, Marijt EW, De Ru AH, Schaafsma MR, Willemze R, Van Veelen PA & Falkenburg JHF (2006), ATP dependent interferon responsive (ADIR) gene encodes an activation induced minor histocompatibility antigen recognized on multiple myeloma by CD8+T cells., Blood 108(11).
- von dem Borne PA, Luxemburg-Heijs SAP, Heemskerk MHM, Jedema I, Mulder A, Willemze R & Falkenburg JHF (2006), Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells, Leukemia 20(6).
- Barge RMY, Starrenburg CWJ, Falkenburg JHF, Fibbe WE, Marijt EW & Willemze R (2006), Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath 'in the bag' as T-cell depletion: the Leiden experience, Bone Marrow Transplantation 37(12).
- Slager EH, Honders MW, van der Meijden ED, van Luxemburg-Heijs SAP, Kloosterboer FM, Kester MGD, Jedema I, Marijt WAE, Schaafsma MR, Willemze R & Falkenburg JHF (2006), Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer, Blood 107(12).
- Hoogendoorn M, Wolbers JO, Smit WM, Schaafsma MR, Jedema I, Barge RMY, Willemze R & Falkenburg JHF (2005), Primary allogeneic T-Cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation, Clinical Cancer Research 11(14).
- Lim FTH, Kanhai HHH & Falkenburg JHF (2005), Characterization of the human CD34(+) hematopoietic progenitor cell compartment during the second trimester of pregnancy, Haematologica 90(2).
- van der Veken LT, Hoogeboom M, de Paus RA, Willemze R, Falkenburg JHF & Heemskerk MHM (2005), HLA class II restricted T-cell receptor gene transfer generates CD4(+) T cells with helper activity as well as cytotoxic capacity, Gene Therapy 12(23).
- Nijmeijer BA, van Schie MLJ, Verzaal P, Willemze R & Falkenburg JHF (2005), Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia, Experimental Hematology 33(10).
- Kloosterboer FM, van Luxemburg-Heijs SAP, van Soest RA, van Egmond HM, Barbui AM, Strijbosch MPW, Willemze R & Falkenburg JHF (2005), Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFN gamma-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion, Leukemia 19(1).
- Barge RMY, Steel E, Starrenburg CW, Beaumont MF, Smit WM, Schaafsma MR, Fibbe WE, Falkenburg JHF & Willemze R (2005), Toxicity and efficacy of donor lymphocyte infusions for patients with acute myelold leukaemia, Bone Marrow Transplantation 35.
- Kloosterboer FM, van Luxemburg-Heijs SAP, van Soest RA, van Egmond HME, Willemze R & Falkenburg JHF (2005), Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia, Blood 106(12).
- Von dem Borne PA, Beaumont F, Starrenburg I, Oudshoom MA, Hale G, Falkenburg JHF, Fibbe WE, Willemze R & Barge RMY (2005), Minimal GvHD after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with Campath-1H, Bone Marrow Transplantation 35.
- Schimmel KJM, Nijmeijer BA, van Schie MLJ, Falkenburg JHF & Guchelaar HJ (2005), Toxicity and effectivity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia (ALL)., Blood 106(11).
- Kluin-Nelemans HC, Buck G, le Cessie S, Richards S, Beverloo HB, Falkenburg JHF, Littlewood T, Muus P, Bareford D, van der Lelie H, Green AR, Roozendaal KJ, Milne AE, Chapman CS & Shepherd P (2004), Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups, Blood 103(12).
- Posthuma EFM, Van Bergen CAM, Kester MGD, de Paus RA, van Veelen PA, de Ru AH, Drijfhout JW, Lurvink EGA, Willemze R & Falkenburg JHF (2004), Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated, Haematologica 89(9).
- Hoogendoorn M, Wolbers JO, Smit WM, Schaafsma MR, Barge RMY, Willemze R & Falkenburg JHF (2004), Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy, Leukemia 18(7).
- Jedema I, van der Werff NM, Barge RMY, Willemze R & Falkenburg JHF (2004), New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population, Blood 103(7).
- Kloosterboer FM, van Luxernburg-Heijs SAP, Willemze R & Falkenburg JHF (2004), Umbilical cord blood-naive T cells but not adult blood-naive T cells require HLA class II on antigen-presenting cells for allo-immune activation, Human Immunology 65(4).
- Jedema I, Barge RMY, Frankel AE, Willemze R & Falkenburg JHF (2004), Acute myeloid leukemia cells in G(0) phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins, Experimental Hematology 32(2).
- Barge RMY, Marijt WAF, Osanto S, Starrenburg CWJ, Schaafsma MR, Smit WM, Fibbe WE, Falkenburg JHF & Willemze R (2004), High dose of in-vitro T-cell depleted CD34+donor peripheral stem cells after non-myeloablative conditioning accelerates platelet recovery but does not establish complete donor chimerism, Bone Marrow Transplantation 33.
- Kloosterboer FM, van Luxemburg-Heijs SAP, van Soest RA, Barbui AM, van Egmond HM, Strijbosch MPW, Kester MGD, Marijt WAF, Goulmy E, Willemze R & Falkenburg JHF (2004), Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells, Leukemia 18(4).
- Heemskerk MHM, Hoogeboom M, Hagedoorn R, Kester MGD, Willemze R & Falkenburg JHF (2004), Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer, Journal of Experimental Medicine 199(7).
- Posthuma EFM, Marijt EWAF, Barge RMY, van Soest RA, Baas IO, Starrenburg CWJI, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R & Falkenburg JHF (2004), alpha-interferon with very-low-dose donor lymphocyte infusion for Hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable Graft-versus-Host disease, Biology of Blood and Marrow Transplantation 10(3).
- Oosten LEM, Blokland E, van Halteren AGS, Curtsinger J, Mescher MF, Falkenburg JHF, Mutis T & Goulmy E (2004), Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes, Blood 104(1).
- von Bergh ARM, Wijers PM, Groot AJ, van Zelderen-Bhola S, Falkenburg JHF, Kluin PM & Schuuring E (2004), Identification of a novel RAS GTPase-activating protein (RASGAP) gene at 9q34 as an MLL fusion partner in a patient with de novo acute myeloid leukemia, Genes, Chromosomes and Cancer 39(4).
- Falkenburg JHF & Willemze R (2004), Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia.
- Jedema I, Barge RMY, van der Velden VHJ, Nijmeijer BA, van Dongen JJM, Willemze R & Falkenburg JHF (2004), Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity, Leukemia 18(2).
- Spaenij-Dekking EHA, Van der Meijden ED, Falkenburg JHF & Kluin-Nelemans JC (2004), Clonally expanded T cells in hairy cell leukemia patients are not leukemia specific, Leukemia 18(1).
- von dem Borne PA, Beaumont F, Starrenburg I, Oudshoorn MA, Hale G, Falkenburg JHF, Fibbe WE, Willemze R & Barge RMY (2004), Improved long term survival with minimal GVHD after myeloablative unrelated donor stem cell transplantation using in vitro and in vivo T cell depletion with CAMPATH-1H., Blood 104(11).
- Falkenburg JHF (2004), Immunotherapy of hematological malignancies with dendritic cells, Hematology Journal 5.
- Falkenburg JHF, van de Corput L, Marijt EWA & Willemze R (2003), Minor histocompatibility antigens in human stem cell transplantation, Experimental Hematology 31(9).
- Barge RMY, Osanto S, Marijt WAFE, Starrenburg CWJI, Fibbe WE, Nortier JWRH, Falkenburg JHF & Willemze R (2003), Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors, Experimental Hematology 31(10).
- Spierings E, Vermeulen CJ, Vogt MH, Doerner LEE, Falkenburg JHF, Mutis T & Goulmy E (2003), Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation, Lancet 362(9384).
- Barge RMY, Marijt WAF, Osanto S, Starrenburg CWJ, Smit W, Fibbe WE, Falkenburg JHF & Willemze R (2003), Non-myeloablative in vitro T-cell depleted allogeneic stem cell transplantation is a good platform for subsequent cellular immunotherapy in patients with hematological malignancies and solid tumors, Bone Marrow Transplantation 31.
- Jedema I, Barge RMY, Willemze R & Falkenburg JHF (2003), High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G(1) phase of the cell cycle and can be increased by interferon treatment, Leukemia 17(3).
- Laurin D, Spierings E, Bertrand Y, Vogt M, Falkenburg JHF, Vermeulen C, Galambrun C, Souillet G, Gebuhrer L, Rigal D, Goulmy E & Eljaafari A (2003), In vitro priming of HLA-identical T cells with allogeneic dendritic cells allows identification of an MHC class II-restricted minor Histocompatibility Ag peptide encoded by DBY, Genes and Immunity 4.
- Spaenij-Dekking EHA, Van Delft J, Van der Meijden E, Hiemstra HS, Falkenburg JHF, Koning F, Drijfhout JW & Kluin-Nelemans JC (2003), Synaptojanin 2 is recognized by HLA class II-restricted hairy cell leukemia-specific T cells, Leukemia 17(12).
- van der Hoorn MAWG, van Luxemburg-Heijs SAP, van Bergen CAM, Bongaerts R, Willemze R & Falkenburg JHF (2003), The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia, Methods 31(2).
- Marijt EWA, van Bergen KAM, Bongaerts R, Esendam BHJ, van der Hoorn MAWG, van Luxemburg-Heijs SAP, van der Muijsenberg JW, Wolbers JO, van der Werff N, Wafelman AR, Willemze R & Falkenburg JHF (2003), Treatment of relapsed leukemia after allogeneic stem cell transplantation with in-vitro generated leukemia-reactive, Blood 102(11).
- Barge RMY, Marijt EWA, Osanto S, Starrenburg I, Smit WM, Schaafsma MR, Fibbe WE, Falkenburg JHF & Willemze R (2003), Depleted non-myeloablative stem cell transplantation induces rapid conversion to full donor chimerism in patients with high risk malignancies., Blood 102(11).
- Heemskerk MHM, Hoogeboom M, de Paus RA, Kester MGD, van der Hoorn MAWG, Goulmy E, Willemze R & Falkenburg JHF (2003), Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region, Blood 102(10).
- Jedema I, Barge RMY, Nijmeijer BA, Willemze R & Falkenburg JHF (2003), Recruitment of leukemic cells from G(0) phase of the cell cycle by interferons results in conversion of resistance to daunorubicin, Leukemia 17(10).
- Marijt WAE, Heemskerk MHM, Kloosterboer FM, Goulmy E, Kester MGD, van der Hoorn MAWG, van Luxemburg-Heys SAP, Hoogeboom M, Mutis T, Drijfhout JW, van Rood JJ, Willemze R & Falkenburg JHF (2003), Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia, Proceedings of the National Academy of Sciences 100(5).
- Nijmeijer BA, Willemze R & Falkenburg JHF (2002), An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice, Blood 100(2).
- Wilpshaar J, Joekes EC, Lim FTH, Van Leeuwen GAM, Van den Boogaard PJ, Kanhai HHH, Willemze R & Falkenburg JHF (2002), Magnetic resonance imaging of fetal bone marrow for quantitative definition of the human fetal stem cell compartment, Blood 100(2).
- Noort WA, Kruisselbrink AB, in't Anker PS, Kruger M, van Bezooijen RL, de Paus RA, Heemskerk MHM, Lowik CWGM, Falkenburg JHF, Willemze R & Fibbe WE (2002), Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice, Experimental Hematology 30(8).
- Mutis T, Ghoreschi K, Schrama E, Kamp J, Heemskerk M, Falkenburg JHF, Wilke M & Goulmy E (2002), Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA, Biology of Blood and Marrow Transplantation 8(8).
- Falkenburg JHF, Marijt WAF, Heemskerk MHM & Willemze R (2002), Minor histocomplatibility antigens as targets of graft-versus-leukemia reactions, Current Opinion in Hematology 9(6).
- Wilpshaar J, Bhatia M, Kanhai HHH, Breese R, Heilman DK, Johnson CS, Falkenburg JHF & Srour EF (2002), Engraftment potential of human fetal hematopoietic cells in NOD/SCID mice is not restricted to mitotically quiescent cells, Blood 100(1).
- Kloosterboer FM, van Luxemburg-Heijs SAP, Barbui AM, Strijbosch MPW, Marijt WAF, Goulmy E, Willemze R & Falkenburg JHF (2002), Direct cloning of tumor-reactive T cells from peripheral blood of patients treated with donor lymphocyte infusion (DLI) shows the presence of high numbers of hematopoiesis-restricted minor histocompatibility antigen (mHag) HA-1 and HA-2 specific CD8+T cells., Blood 100(11).
- Barge RMY, Marijt E, Osanto S, Starrenburg I, Smit W, Fibbe WE, Falkenburg JHF & Willemze R (2002), A two step non-myeloablative allogeneic (NM-allo) transplantation strategy using in vitro T-cell depleted G-CSF mobilized peripheral blood stem cells followed by donor lymphocyte infusions (DLI)., Blood 100(11).
- Brouwer RE, van der Heiden P, Schreuder GMT, Mulder A, Datema G, Anholts JDH, Willemze R, Claas FHJ & Falkenburg JHF (2002), Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon, Human Immunology 63(3).
- Vogt MHJ, van den Muijsenberg JW, Goulmy E, Spierings E, Kluck P, Kester MG, van Soest RA, Drijfhout JW, Willemze R & Falkenburg JHF (2002), The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease, Blood 99(8).
- Spierings E, Vermeulen CJ, Mutis T, Vogt MH, Falkenburg JHF & Goulmy E (2002), Complete anti-H-Y immune response clarifies poorer graft outcome of sex-mismatched transplants, Tissue Antigens 59.
- Brouwer RE, Hoefnagel J, van der Burg BB, Jedema I, Zwinderman KH, Starrenburg ICW, Kluin-Nelemans HC, Barge RMY, Willemze R & Falkenburg JHF (2001), Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis, British Journal of Haematology 115(2).
- Wilpshaar J, Noort WA, Kanhai HHH, Willemze R & Falkenburg JHF (2001), Engraftment potential into NOD/SCID mice of CD34(+) cells derived from human fetal liver as compared to fetal bone marrow, Haematologica 86(10).
- Marijt WAF & Falkenburg JHF (2001), Specific T cell therapy in leukemia, Journal of Hematotherapy and Stem Cell Research 10(4).
- Noort WA, Wilpshaar J, Hertogh CDP, Rad M, Lurvink EGA, van Luxemburg-Heijs SAP, Zwinderman K, Verwey RA, Willemze R & Falkenburg JHF (2001), Similar myeloid recovery despite superior overall engraftment in NOD/SCID mice after transplantation of human CD34(+) cells from umbilical cord blood as compared to adult sources, Bone Marrow Transplantation 28(2).
- Barge RMY, Brouwer RE, Beersma MFC, Starrenburg CWJ, Zwinderman AH, Hale G, Waldmann H, den Ottolander GJ, Falkenburg JHF, Willemze R & Fibbe WE (2001), Graft outcome - Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short-and long-term outcome, Bone Marrow Transplantation 27(10).
- Heemskerk MHM, de Paus RA, Lurvink EGA, Koning F, Mulder A, Willemze R, van Rood JJ & Falkenburg JHF (2001), Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex, Proceedings of the National Academy of Sciences 98(12).
- Nijmeijer BA, Mollevanger P, van Zelderen-Bhola SL, Kluin-Nelemans HC, Willemze R & Falkenburg JHF (2001), Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice, Experimental Hematology 29(3).
- Vogt MHJ, de Paus RA, Voogt PJ, Willemze R & Falkenburg JHF (2000), DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection.
- Posthuma EFM, Falkenburg JHF, Apperley JF, Gratwohl A, Hertenstein B, Schipper RF, Oudshoorn M, von Biezen JH, Hermans J, Willemze R, Roosnek E & Niederwieser D (2000), HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML).
- Brouwer RE, van der Hoorn M, Kluin-Nelemans HC, van Zelderen-Bhola S, Willemze R & Falkenburg JHF (2000), The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses.
- Lim FTH, Scherjon SA, van Beckhoven JM, Brand A, Kanhai HHH, Hermans JMH & Falkenburg JHF (2000), Association of stress during delivery with increased numbers of nucleated cells and hematopoietic progenitor cells in umbilical cord blood, American Journal of Obstetrics and Gynecology 183(5).
- Vogt MHJ, Goulmy E, Kloosterboer FM, Blokland E, de Paus RA, Willemze R & Falkenburg JHF (2000), UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition, Blood 96(9).
- Wilpshaar J, Falkenburg JHF, Tong X, Noort WA, Breese R, Heilman D, Kanhai H, Orschell-Traycoff CM & Srour EF (2000), Similar repopulating capacity of mitotically active and resting umbilical cord blood CD34(+) cells in NOD/SCID mice, Blood 96(6).
- Lid
- Lid en plaatsvervangend voorzitter
- Lid
- Lid
- Lid
- Lid
- Lid van Wetenschappelijk Comité
- Lid
- Lid
- Lid
- Bestuurslid
- Voorzitter Adviescommissie Translatie
- Lid National Advisory Board
- Lid Wetenschappelijke Raad